Search

Your search keyword '"LA BARBERA, D."' showing total 41 results
Start Over Author "LA BARBERA, D." Topic schizophrenia
41 results on '"LA BARBERA, D."'

1. The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis.

Author

Alameda L, Rodriguez V, Di Forti M, Spinazzola E, Trotta G, Arango C, Arrojo M, Bernardo M, Bobes J, de Haan L, Del-Ben CM, Gayer-Anderson C, Sideli L, Jones PB, Kirkbride JB, La Cascia C, Tripoli G, Ferraro L, La Barbera D, Lasalvia A, Tosato S, Llorca PM, Menezes PR, van Os J, Rutten BP, Santos JL, Sanjuán J, Selten JP, Szöke A, Tarricone I, Tortelli A, Velthorst E, Jongsma HE, Vassos E, Quattrone D, Murray RM, and Aas M

Subjects
Humans, Female, Male, Adult, Case-Control Studies, Young Adult, Gene-Environment Interaction, Adolescent, Risk Factors, Middle Aged, Genetic Risk Score, Multifactorial Inheritance, Psychotic Disorders genetics, Psychotic Disorders psychology, Adverse Childhood Experiences psychology, Bipolar Disorder genetics, Bipolar Disorder psychology, Depressive Disorder, Major genetics, Schizophrenia genetics, Genetic Predisposition to Disease
Abstract

Childhood adversity is associated with various clinical dimensions in psychosis; however, how genetic vulnerability shapes the adversity-associated psychopathological signature is yet to be studied. We studied data of 583 First Episode Psychosis (FEP) cases from the EU-GEI FEP case-control study, including Polygenic risk scores for major depressive disorder (MDD-PRS), bipolar disorder (BD-PRS) and schizophrenia (SZ-PRS); childhood adversity measured with the total score of the Childhood Trauma Questionnaire (CTQ); and positive, negative, depressive and manic psychopathological domains from a factor model of transdiagnostic dimensions. Genes and environment interactions were explored as a departure from a multiplicative effect of PRSs and total CTQ on each dimension. Analyses were adjusted for age, sex, 10 PCA, site of recruitment and for medication. A childhood adversity and PRS multiplicative interaction was observed between A) the CTQ and MDD-PRS on the predominance of positive (β = 0.42, 95% CI = [0.155, 0.682], p = 0.004); and depressive (β = 0.33, 95% CI = [0.071, 0.591], p = 0.013) dimensions; B) between the CTQ and BD-PRS on the positive dimension (β = 0.45, 95% CI = [0.106, 0.798], p = 0.010), and C) with the CTQ and SZ-PRS on the positive dimension (β = -0.34, 95% CI = [-0.660, -0.015], p = 0.040). Bonferroni corrected p-value of significance was set at 0.0125. In conclusion, despite being underpowered, this study suggests that genetic liability for MDD and BD may have a moderating effect on the sensibility of childhood adversity on depressive and positive psychotic dimensions. This supports the hypothesis of an affective pathway to psychosis in those exposed to childhood adversity., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

2. Tobacco use in first-episode psychosis, a multinational EU-GEI study.

Author

Sánchez-Gutiérrez T, Rodríguez-Toscano E, Roldán L, Ferraro L, Parellada M, Calvo A, López G, Rapado-Castro M, La Barbera D, La Cascia C, Tripoli G, Di Forti M, Murray RM, Quattrone D, Morgan C, van Os J, García-Portilla P, Al-Halabí S, Bobes J, de Haan L, Bernardo M, Santos JL, Sanjuán J, Arrojo M, Ferchiou A, Szoke A, Rutten BP, Stilo S, D'Andrea G, Tarricone I, Díaz-Caneja CM, and Arango C

Subjects
Humans, Tobacco Use epidemiology, Psychotic Disorders epidemiology, Psychotic Disorders diagnosis, Schizophrenia epidemiology, Cannabis adverse effects, Substance-Related Disorders
Abstract

Background: Tobacco is a highly prevalent substance of abuse in patients with psychosis. Previous studies have reported an association between tobacco use and schizophrenia. The aim of this study was to analyze the relationship between tobacco use and first-episode psychosis (FEP), age at onset of psychosis, and specific diagnosis of psychosis., Methods: The sample consisted of 1105 FEP patients and 1355 controls from the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We assessed substance use with the Tobacco and Alcohol Questionnaire and performed a series of regression analyses using case-control status, age of onset of psychosis, and diagnosis as outcomes and tobacco use and frequency of tobacco use as predictors. Analyses were adjusted for sociodemographic characteristics, alcohol, and cannabis use., Results: After controlling for cannabis use, FEP patients were 2.6 times more likely to use tobacco [ p ⩽ 0.001; adjusted odds ratio (AOR) 2.6; 95% confidence interval (CI) [2.1-3.2]] and 1.7 times more likely to smoke 20 or more cigarettes a day ( p = 0.003; AOR 1.7; 95% CI [1.2-2.4]) than controls. Tobacco use was associated with an earlier age at psychosis onset ( β = -2.3; p ⩽ 0.001; 95% CI [-3.7 to -0.9]) and was 1.3 times more frequent in FEP patients with a diagnosis of schizophrenia than in other diagnoses of psychosis (AOR 1.3; 95% CI [1.0-1.8]); however, these results were no longer significant after controlling for cannabis use., Conclusions: Tobacco and heavy-tobacco use are associated with increased odds of FEP. These findings further support the relevance of tobacco prevention in young populations.

Published
2023
Full Text
View/download PDF

3. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case-control study.

Author

Sideli L, Aas M, Quattrone D, La Barbera D, La Cascia C, Ferraro L, Alameda L, Velthorst E, Trotta G, Tripoli G, Schimmenti A, Fontana A, Gayer-Anderson C, Stilo S, Seminerio F, Sartorio C, Marrazzo G, Lasalvia A, Tosato S, Tarricone I, Berardi D, D'Andrea G, Arango C, Arrojo M, Bernardo M, Bobes J, Sanjuán J, Santos JL, Menezes PR, Del-Ben CM, Jongsma HE, Jones PB, Kirkbride JB, Llorca PM, Tortelli A, Pignon B, de Haan L, Selten JP, Van Os J, Rutten BP, Bentall R, Di Forti M, Murray RM, Morgan C, and Fisher HL

Subjects
Adult, Humans, Child, Case-Control Studies, Cognition, Psychotic Disorders genetics, Schizophrenia epidemiology, Schizophrenia genetics, Child Abuse
Abstract

This study investigated if the association between childhood maltreatment and cognition among psychosis patients and community controls was partially accounted for by genetic liability for psychosis. Patients with first-episode psychosis (N = 755) and unaffected controls (N = 1219) from the EU-GEI study were assessed for childhood maltreatment, intelligence quotient (IQ), family history of psychosis (FH), and polygenic risk score for schizophrenia (SZ-PRS). Controlling for FH and SZ-PRS did not attenuate the association between childhood maltreatment and IQ in cases or controls. Findings suggest that these expressions of genetic liability cannot account for the lower levels of cognition found among adults maltreated in childhood., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

4. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study.

Author

Rodriguez V, Alameda L, Quattrone D, Tripoli G, Gayer-Anderson C, Spinazzola E, Trotta G, Jongsma HE, Stilo S, La Cascia C, Ferraro L, La Barbera D, Lasalvia A, Tosato S, Tarricone I, Bonora E, Jamain S, Selten JP, Velthorst E, de Haan L, Llorca PM, Arrojo M, Bobes J, Bernardo M, Arango C, Kirkbride J, Jones PB, Rutten BP, Richards A, Sham PC, O'Donovan M, Van Os J, Morgan C, Di Forti M, Murray RM, and Vassos E

Subjects
Humans, Case-Control Studies, Genetic Predisposition to Disease, Risk Factors, Multifactorial Inheritance, Schizophrenia diagnosis, Schizophrenia genetics, Psychotic Disorders diagnosis, Psychotic Disorders genetics, Psychotic Disorders psychology
Abstract

Background: Schizophrenia (SZ), bipolar disorder (BD) and depression (D) run in families. This susceptibility is partly due to hundreds or thousands of common genetic variants, each conferring a fractional risk. The cumulative effects of the associated variants can be summarised as a polygenic risk score (PRS). Using data from the EUropean Network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) first episode case-control study, we aimed to test whether PRSs for three major psychiatric disorders (SZ, BD, D) and for intelligent quotient (IQ) as a neurodevelopmental proxy, can discriminate affective psychosis (AP) from schizophrenia-spectrum disorder (SSD)., Methods: Participants (842 cases, 1284 controls) from 16 European EU-GEI sites were successfully genotyped following standard quality control procedures. The sample was stratified based on genomic ancestry and analyses were done only on the subsample representing the European population (573 cases, 1005 controls). Using PRS for SZ, BD, D, and IQ built from the latest available summary statistics, we performed simple or multinomial logistic regression models adjusted for 10 principal components for the different clinical comparisons., Results: In case-control comparisons PRS-SZ, PRS-BD and PRS-D distributed differentially across psychotic subcategories. In case-case comparisons, both PRS-SZ [odds ratio (OR) = 0.7, 95% confidence interval (CI) 0.54-0.92] and PRS-D (OR = 1.31, 95% CI 1.06-1.61) differentiated AP from SSD; and within AP categories, only PRS-SZ differentiated BD from psychotic depression (OR = 2.14, 95% CI 1.23-3.74)., Conclusions: Combining PRS for severe psychiatric disorders in prediction models for psychosis phenotypes can increase discriminative ability and improve our understanding of these phenotypes. Our results point towards the potential usefulness of PRSs in specific populations such as high-risk or early psychosis phases.

Published
2023
Full Text
View/download PDF

5. First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data.

Author

Ferraro L, Quattrone D, La Barbera D, La Cascia C, Morgan C, Kirkbride JB, Cardno AG, Sham P, Tripoli G, Sideli L, Seminerio F, Sartorio C, Szoke A, Tarricone I, Bernardo M, Rodriguez V, Stilo SA, Gayer-Anderson C, de Haan L, Velthorst E, Jongsma H, Bart RBP, Richards A, Arango C, Menezez PR, Lasalvia A, Tosato S, Tortelli A, Del Ben CM, Selten JP, Jones PB, van Os J, Di Forti M, Vassos E, and Murray RM

Subjects
Adolescent, Humans, Risk Factors, Cluster Analysis, Psychotic Disorders epidemiology, Psychotic Disorders genetics, Psychotic Disorders psychology, Schizophrenia epidemiology, Schizophrenia genetics, Schizophrenia diagnosis, Bipolar Disorder genetics
Abstract

Cluster studies identified a subgroup of patients with psychosis whose premorbid adjustment deteriorates before the onset, which may reflect variation in genetic influence. However, other studies reported a complex relationship between distinctive patterns of cannabis use and cognitive and premorbid impairment that is worthy of consideration. We examined whether: (1) premorbid social functioning (PSF) and premorbid academic functioning (PAF) in childhood and adolescence and current intellectual quotient (IQ) define different clusters in 802 first-episode of psychosis (FEP) patients; resulting clusters vary in (2) polygenic risk scores (PRSs) for schizophrenia (SCZ&#95;PRS), bipolar disorder (BD&#95;PRS), major depression (MD&#95;PRS), and IQ (IQ&#95;PRS), and (3) patterns of cannabis use, compared to 1,263 population-based controls. Four transdiagnostic clusters emerged (BIC = 2268.5): (1) high-cognitive-functioning (n = 205), with the highest IQ (Mean = 106.1, 95% CI: 104.3, 107.9) and PAF, but low PSF. (2) Low-cognitive-functioning (n = 223), with the lowest IQ (Mean = 73.9, 95% CI: 72.2, 75.7) and PAF, but normal PSF. (3) Intermediate (n = 224) (Mean&#95;IQ = 80.8, 95% CI: 79.1, 82.5) with low-improving PAF and PSF. 4) Deteriorating (n = 150) (Mean&#95;IQ = 80.6, 95% CI: 78.5, 82.7), with normal-deteriorating PAF and PSF. The PRSs explained 7.9% of between-group membership. FEP had higher SCZ&#95;PRS than controls [F(4,1319) = 20.4, P < .001]. Among the clusters, the deteriorating group had lower SCZ&#95;PRS and was likelier to have used high-potency cannabis daily. Patients with FEP clustered according to their premorbid and cognitive abilities. Pronounced premorbid deterioration was not typical of most FEP, including those more strongly predisposed to schizophrenia, but appeared in a cluster with a history of high-potency cannabis use., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.)

Published
2023
Full Text
View/download PDF

6. Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study.

Author

Tripoli G, Quattrone D, Ferraro L, Gayer-Anderson C, La Cascia C, La Barbera D, Sartorio C, Seminerio F, Rodriguez V, Tarricone I, Berardi D, Jamain S, Arango C, Tortelli A, Llorca PM, de Haan L, Velthorst E, Bobes J, Bernardo M, Sanjuán J, Luis Santos J, Arrojo M, Marta Del-Ben C, Rossi Menezes P, van der Ven E, Jones PB, Jongsma HE, Kirkbride JB, Tosato S, Lasalvia A, Richards A, O'Donovan M, Rutten BPF, van Os J, Morgan C, Sham PC, Di Forti M, Murray RM, and Murray GK

Subjects
Case-Control Studies, Emotions, Facial Expression, Humans, Psychiatric Status Rating Scales, Depressive Disorder, Major complications, Depressive Disorder, Major genetics, Facial Recognition, Psychotic Disorders complications, Schizophrenia complications, Schizophrenia genetics
Abstract

Background and Hypothesis: Facial Emotion Recognition is a key domain of social cognition associated with psychotic disorders as a candidate intermediate phenotype. In this study, we set out to investigate global and specific facial emotion recognition deficits in first-episode psychosis, and whether polygenic liability to psychotic disorders is associated with facial emotion recognition., Study Design: 828 First Episode Psychosis (FEP) patients and 1308 population-based controls completed assessments of the Degraded Facial Affect Recognition Task (DFAR) and a subsample of 524 FEP and 899 controls provided blood or saliva samples from which we extracted DNA, performed genotyping and computed polygenic risk scores for schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MD)., Study Results: A worse ability to globally recognize facial emotion expressions was found in patients compared with controls [B= -1.5 (0.6), 95% CI -2.7 to -0.3], with evidence for stronger effects on negative emotions (fear [B = -3.3 (1.1), 95% CI -5.3 to -1.2] and anger [B = -2.3 (1.1), 95% CI -4.6 to -0.1]) than on happiness [B = 0.3 (0.7), 95% CI -1 to 1.7]. Pooling all participants, and controlling for confounds including case/control status, facial anger recognition was associated significantly with Schizophrenia Polygenic Risk Score (SZ PRS) [B = -3.5 (1.7), 95% CI -6.9 to -0.2]., Conclusions: Psychosis is associated with impaired recognition of fear and anger, and higher SZ PRS is associated with worse facial anger recognition. Our findings provide evidence that facial emotion recognition of anger might play a role as an intermediate phenotype for psychosis., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.)

Published
2022
Full Text
View/download PDF

7. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.

Author

Quattrone D, Reininghaus U, Richards AL, Tripoli G, Ferraro L, Quattrone A, Marino P, Rodriguez V, Spinazzola E, Gayer-Anderson C, Jongsma HE, Jones PB, La Cascia C, La Barbera D, Tarricone I, Bonora E, Tosato S, Lasalvia A, Szöke A, Arango C, Bernardo M, Bobes J, Del Ben CM, Menezes PR, Llorca PM, Santos JL, Sanjuán J, Arrojo M, Tortelli A, Velthorst E, Berendsen S, de Haan L, Rutten BPF, Lynskey MT, Freeman TP, Kirkbride JB, Sham PC, O'Donovan MC, Cardno AG, Vassos E, van Os J, Morgan C, Murray RM, Lewis CM, and Di Forti M

Subjects
Humans, Linear Models, Risk Factors, Cannabis, Psychotic Disorders diagnosis, Psychotic Disorders genetics, Schizophrenia genetics
Abstract

Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms and experiences using item response bi-factor modelling. Linear regression was used to test the associations between these dimensions and SZ-PRS, as well as the combined effect of SZ-PRS and cannabis use on the dimensions of positive psychotic symptoms and experiences. We found associations between SZ-PRS and (1) both negative (B = 0.18; 95%CI 0.03-0.33) and positive (B = 0.19; 95%CI 0.03-0.35) symptom dimensions in 617 FEP patients, regardless of their categorical diagnosis; and (2) all the psychotic experience dimensions in 979 controls. We did not observe associations between SZ-PRS and the general and affective dimensions in FEP. Daily and current cannabis use were associated with the positive dimensions in FEP (B = 0.31; 95%CI 0.11-0.52) and in controls (B = 0.26; 95%CI 0.06-0.46), over and above SZ-PRS. We provide evidence that genetic liability to schizophrenia and cannabis use map onto transdiagnostic symptom dimensions, supporting the validity and utility of the dimensional representation of psychosis. In our sample, genetic liability to schizophrenia correlated with more severe psychosis presentation, and cannabis use conferred risk to positive symptomatology beyond the genetic risk. Our findings support the hypothesis that psychotic experiences in the general population have similar genetic substrates as clinical disorders., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

8. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.

Author

Quattrone D, Ferraro L, Tripoli G, La Cascia C, Quigley H, Quattrone A, Jongsma HE, Del Peschio S, Gatto G, Gayer-Anderson C, Jones PB, Kirkbride JB, La Barbera D, Tarricone I, Berardi D, Tosato S, Lasalvia A, Szöke A, Arango C, Bernardo M, Bobes J, Del Ben CM, Menezes PR, Llorca PM, Santos JL, Sanjuán J, Tortelli A, Velthorst E, de Haan L, Rutten BPF, Lynskey MT, Freeman TP, Sham PC, Cardno AG, Vassos E, van Os J, Morgan C, Reininghaus U, Lewis CM, Murray RM, and Di Forti M

Subjects
Humans, Case-Control Studies, Gene-Environment Interaction, Cannabis adverse effects, Psychotic Disorders epidemiology, Psychotic Disorders complications, Schizophrenia epidemiology, Schizophrenia complications, Marijuana Abuse epidemiology, Marijuana Abuse complications
Abstract

Background: Daily use of high-potency cannabis has been reported to carry a high risk for developing a psychotic disorder. However, the evidence is mixed on whether any pattern of cannabis use is associated with a particular symptomatology in first-episode psychosis (FEP) patients., Method: We analysed data from 901 FEP patients and 1235 controls recruited across six countries, as part of the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We used item response modelling to estimate two bifactor models, which included general and specific dimensions of psychotic symptoms in patients and psychotic experiences in controls. The associations between these dimensions and cannabis use were evaluated using linear mixed-effects models analyses., Results: In patients, there was a linear relationship between the positive symptom dimension and the extent of lifetime exposure to cannabis, with daily users of high-potency cannabis having the highest score ( B = 0.35; 95% CI 0.14-0.56). Moreover, negative symptoms were more common among patients who never used cannabis compared with those with any pattern of use ( B = -0.22; 95% CI -0.37 to -0.07). In controls, psychotic experiences were associated with current use of cannabis but not with the extent of lifetime use. Neither patients nor controls presented differences in depressive dimension related to cannabis use., Conclusions: Our findings provide the first large-scale evidence that FEP patients with a history of daily use of high-potency cannabis present with more positive and less negative symptoms, compared with those who never used cannabis or used low-potency types.

Published
2021
Full Text
View/download PDF

9. The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme.

Author

Gayer-Anderson C, Jongsma HE, Di Forti M, Quattrone D, Velthorst E, de Haan L, Selten JP, Szöke A, Llorca PM, Tortelli A, Arango C, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Parellada M, Tarricone I, Berardi D, Ruggeri M, Lasalvia A, Ferraro L, La Cascia C, La Barbera D, Menezes PR, Del-Ben CM, Rutten BP, van Os J, Jones PB, Murray RM, Kirkbride JB, and Morgan C

Subjects
Adolescent, Adult, Brazil epidemiology, Case-Control Studies, Ethnicity, Europe epidemiology, Female, Humans, Incidence, Male, Middle Aged, Young Adult, Gene-Environment Interaction, Schizophrenia epidemiology
Abstract

Purpose: The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study contains an unparalleled wealth of comprehensive data that allows for testing hypotheses about (1) variations in incidence within and between countries, including by urbanicity and minority ethnic groups; and (2) the role of multiple environmental and genetic risk factors, and their interactions, in the development of psychotic disorders., Methods: Between 2010 and 2015, we identified 2774 incident cases of psychotic disorders during 12.9 million person-years at risk, across 17 sites in 6 countries (UK, The Netherlands, France, Spain, Italy, and Brazil). Of the 2774 incident cases, 1130 cases were assessed in detail and form the case sample for case-control analyses. Across all sites, 1497 controls were recruited and assessed. We collected data on an extensive range of exposures and outcomes, including demographic, clinical (e.g. premorbid adjustment), social (e.g. childhood and adult adversity, cannabis use, migration, discrimination), cognitive (e.g. IQ, facial affect processing, attributional biases), and biological (DNA via blood sample/cheek swab). We describe the methodology of the study and some descriptive results, including representativeness of the cohort., Conclusions: This resource constitutes the largest and most extensive incidence and case-control study of psychosis ever conducted.

Published
2020
Full Text
View/download PDF

10. Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use.

Author

Ferraro L, La Cascia C, Quattrone D, Sideli L, Matranga D, Capuccio V, Tripoli G, Gayer-Anderson C, Morgan C, Sami MB, Sham P, de Haan L, Velthorst E, Jongsma HE, Kirkbride JB, Rutten BPF, Richards AL, Roldan L, Arango C, Bernardo M, Bobes J, Sanjuan J, Santos JL, Arrojo M, Tarricone I, Tortelli A, Szöke A, Del-Ben CM, Selten JP, Lynskey M, Jones PB, Van Os J, La Barbera D, Murray RM, and Di Forti M

Subjects
Adolescent, Adult, Case-Control Studies, Comorbidity, Female, Humans, Male, Middle Aged, Young Adult, Intelligence physiology, Marijuana Use epidemiology, Psychosocial Functioning, Psychotic Disorders epidemiology, Schizophrenia epidemiology, Social Adjustment
Abstract

Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic patients who had ever used cannabis compared to patients without any history of use. We did not expect such differences in controls. In both patients and controls, IQ was 3 points higher among occasional-users than in never-users (mean difference [Mdiff] = 2.9, 95% CI = [1.2, 4.7]). Both cases and control daily-users had lower AF compared to occasional (Mdiff = -0.3, 95% CI = [-0.5; -0.2]) and never-users (Mdiff = -0.4, 95% CI = [-0.6; -0.2]). Finally, patient occasional (Mdiff = 0.3, 95% CI = [0.1; 0.5]) and daily-users (Mdiff = 0.4, 95% CI = [0.2; 0.6]) had better SF than their never-using counterparts. This difference was not present in controls (Fgroup*frequency(2, 2205) = 4.995, P = .007). Our findings suggest that the better premorbid social functioning of FEP with a history of cannabis use may have contributed to their likelihood to begin using cannabis, exposing them to its reported risk-increasing effects for Psychotic Disorders., (© The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2020
Full Text
View/download PDF

11. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study.

Author

Quattrone D, Di Forti M, Gayer-Anderson C, Ferraro L, Jongsma HE, Tripoli G, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Lasalvia A, Tortelli A, Llorca PM, de Haan L, Velthorst E, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Del-Ben CM, Menezes PR, Selten JP, Jones PB, Kirkbride JB, Richards AL, O'Donovan MC, Sham PC, Vassos E, Rutten BP, van Os J, Morgan C, Lewis CM, Murray RM, and Reininghaus U

Subjects
Adult, Affective Disorders, Psychotic, Bipolar Disorder psychology, Depression psychology, Europe, Female, Humans, Male, Models, Psychological, Psychiatric Status Rating Scales, ROC Curve, Young Adult, Psychopathology, Psychotic Disorders classification, Psychotic Disorders psychology, Schizophrenia classification, Schizophrenic Psychology
Abstract

Background: The value of the nosological distinction between non-affective and affective psychosis has frequently been challenged. We aimed to investigate the transdiagnostic dimensional structure and associated characteristics of psychopathology at First Episode Psychosis (FEP). Regardless of diagnostic categories, we expected that positive symptoms occurred more frequently in ethnic minority groups and in more densely populated environments, and that negative symptoms were associated with indices of neurodevelopmental impairment., Method: This study included 2182 FEP individuals recruited across six countries, as part of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Symptom ratings were analysed using multidimensional item response modelling in Mplus to estimate five theory-based models of psychosis. We used multiple regression models to examine demographic and context factors associated with symptom dimensions., Results: A bifactor model, composed of one general factor and five specific dimensions of positive, negative, disorganization, manic and depressive symptoms, best-represented associations among ratings of psychotic symptoms. Positive symptoms were more common in ethnic minority groups. Urbanicity was associated with a higher score on the general factor. Men presented with more negative and less depressive symptoms than women. Early age-at-first-contact with psychiatric services was associated with higher scores on negative, disorganized, and manic symptom dimensions., Conclusions: Our results suggest that the bifactor model of psychopathology holds across diagnostic categories of non-affective and affective psychosis at FEP, and demographic and context determinants map onto general and specific symptom dimensions. These findings have implications for tailoring symptom-specific treatments and inform research into the mood-psychosis spectrum.

Published
2019
Full Text
View/download PDF

12. Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice.

Author

Fagiolini A, Aguglia E, Ballerini A, Callista G, Carpiniello B, Clerici M, Corrivetti G, De Fazio P, De Filippis S, De Giorgi S, Favaretto G, Ferri E, Gargiulo G, Giustra MG, La Barbera D, Maina G, Mencacci C, Montagnani G, Panariello A, Pigato G, Tortorella A, Vernacotola L, and Vita A

Subjects
Adult, Delayed-Action Preparations therapeutic use, Female, Humans, Italy, Male, Medication Adherence, Middle Aged, Retrospective Studies, Treatment Outcome, Antipsychotic Agents therapeutic use, Aripiprazole therapeutic use, Schizophrenia drug therapy
Abstract

Objectives: To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia., Methods: Observational, retrospective, non-interventional study involving 261 patients with schizophrenia., Results: Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5; 3) psychotic spectrum schizoid score ≤ 11., Conclusions: A relatively high number of patients (n = 225, 86%) were persistent to A-LAI for at least 6 months. Not surprisingly, very severe patients were more unlikely to be persistent. However, it is noteworthy that a large number of subjects with high CGI score at the time when A-LAI was started (82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7) were persistent. Larger, controlled, prospective and longer studies are warranted., (Copyright © 2019 Elsevier B.V. All rights reserved.)

Published
2019
Full Text
View/download PDF

13. Low incidence of psychosis in Italy: confirmation from the first epidemiological study in Sicily.

Author

Mulè A, Sideli L, Capuccio V, Fearon P, Ferraro L, Kirkbride JB, La Cascia C, Sartorio C, Seminerio F, Tripoli G, Di Forti M, La Barbera D, and Murray RM

Subjects
Adolescent, Adult, Aged, Epidemiologic Studies, Female, Humans, Incidence, Male, Middle Aged, Sicily epidemiology, Young Adult, Psychotic Disorders epidemiology, Schizophrenia epidemiology
Abstract

Purpose: The incidence of psychotic disorders varies in different geographical areas. As there have been no reports from Southern Italy, this study aimed to determine the incidence rate of first-episode psychosis in Palermo, Sicily., Methods: All patients, aged 18-65 years, presenting with a first episode of psychosis (FEP) (ICD-10 F20-29, F30-33) to mental health services in Palermo, were recorded over a 3-year period. Incidence rates of psychotic disorders and their 95% confidence intervals (95% CI) were estimated. Poisson regression was applied to estimate the differences in incidence rate ratio (IRR) by age, sex and migrant status., Results: Two hundred and four FEP participants were identified during the 3 years; 183 (89.7%, males n = 112) participants were native Italians and 21 were migrants (10.3%, males n = 14). The crude incidence of all psychoses was 15.9 (95% CI 13.7-18.1). As predicted, the risk of schizophrenia F20 was higher in males compared to females (adjusted IRR = 1.99, 95% CI 1.36-2.88) and in migrants compared to native Italians (adjusted IRR = 4.02, 95% CI 2.39-6.75)., Conclusions: This study, the first from Sicily, confirms previous findings from Northern Italy that the risk of schizophrenia and other psychoses is much lower in Italian cities than those reported from cities in Northern Europe; the reasons for this disparity may provide important clues to the aetiology of psychosis.

Published
2017
Full Text
View/download PDF

14. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations.

Author

van Os J, Rutten BP, Myin-Germeys I, Delespaul P, Viechtbauer W, van Zelst C, Bruggeman R, Reininghaus U, Morgan C, Murray RM, Di Forti M, McGuire P, Valmaggia LR, Kempton MJ, Gayer-Anderson C, Hubbard K, Beards S, Stilo SA, Onyejiaka A, Bourque F, Modinos G, Tognin S, Calem M, O'Donovan MC, Owen MJ, Holmans P, Williams N, Craddock N, Richards A, Humphreys I, Meyer-Lindenberg A, Leweke FM, Tost H, Akdeniz C, Rohleder C, Bumb JM, Schwarz E, Alptekin K, Üçok A, Saka MC, Atbaşoğlu EC, Gülöksüz S, Gumus-Akay G, Cihan B, Karadağ H, Soygür H, Cankurtaran EŞ, Ulusoy S, Akdede B, Binbay T, Ayer A, Noyan H, Karadayı G, Akturan E, Ulaş H, Arango C, Parellada M, Bernardo M, Sanjuán J, Bobes J, Arrojo M, Santos JL, Cuadrado P, Rodríguez Solano JJ, Carracedo A, García Bernardo E, Roldán L, López G, Cabrera B, Cruz S, Díaz Mesa EM, Pouso M, Jiménez E, Sánchez T, Rapado M, González E, Martínez C, Sánchez E, Olmeda MS, de Haan L, Velthorst E, van der Gaag M, Selten JP, van Dam D, van der Ven E, van der Meer F, Messchaert E, Kraan T, Burger N, Leboyer M, Szoke A, Schürhoff F, Llorca PM, Jamain S, Tortelli A, Frijda F, Vilain J, Galliot AM, Baudin G, Ferchiou A, Richard JR, Bulzacka E, Charpeaud T, Tronche AM, De Hert M, van Winkel R, Decoster J, Derom C, Thiery E, Stefanis NC, Sachs G, Aschauer H, Lasser I, Winklbaur B, Schlögelhofer M, Riecher-Rössler A, Borgwardt S, Walter A, Harrisberger F, Smieskova R, Rapp C, Ittig S, Soguel-dit-Piquard F, Studerus E, Klosterkötter J, Ruhrmann S, Paruch J, Julkowski D, Hilboll D, Sham PC, Cherny SS, Chen EY, Campbell DD, Li M, Romeo-Casabona CM, Emaldi Cirión A, Urruela Mora A, Jones P, Kirkbride J, Cannon M, Rujescu D, Tarricone I, Berardi D, Bonora E, Seri M, Marcacci T, Chiri L, Chierzi F, Storbini V, Braca M, Minenna MG, Donegani I, Fioritti A, La Barbera D, La Cascia CE, Mulè A, Sideli L, Sartorio R, Ferraro L, Tripoli G, Seminerio F, Marinaro AM, McGorry P, Nelson B, Amminger GP, Pantelis C, Menezes PR, Del-Ben CM, Gallo Tenan SH, Shuhama R, Ruggeri M, Tosato S, Lasalvia A, Bonetto C, Ira E, Nordentoft M, Krebs MO, Barrantes-Vidal N, Cristóbal P, Kwapil TR, Brietzke E, Bressan RA, Gadelha A, Maric NP, Andric S, Mihaljevic M, and Mirjanic T

Subjects
Genetic Predisposition to Disease, Humans, Schizophrenia epidemiology, Social Environment, Gene-Environment Interaction, Schizophrenia genetics, Schizophrenic Psychology
Abstract

Recent years have seen considerable progress in epidemiological and molecular genetic research into environmental and genetic factors in schizophrenia, but methodological uncertainties remain with regard to validating environmental exposures, and the population risk conferred by individual molecular genetic variants is small. There are now also a limited number of studies that have investigated molecular genetic candidate gene-environment interactions (G × E), however, so far, thorough replication of findings is rare and G × E research still faces several conceptual and methodological challenges. In this article, we aim to review these recent developments and illustrate how integrated, large-scale investigations may overcome contemporary challenges in G × E research, drawing on the example of a large, international, multi-center study into the identification and translational application of G × E in schizophrenia. While such investigations are now well underway, new challenges emerge for G × E research from late-breaking evidence that genetic variation and environmental exposures are, to a significant degree, shared across a range of psychiatric disorders, with potential overlap in phenotype., (© The Author 2014. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2014
Full Text
View/download PDF

15. Cognitive rehabilitation of schizophrenia through NeuroVr training.

Author

La Paglia F, La Cascia C, Rizzo R, Sideli L, Francomano A, and La Barbera D

Subjects
Combined Modality Therapy, Humans, Schizophrenia diagnosis, Treatment Outcome, Biofeedback, Psychology methods, Cognitive Behavioral Therapy methods, Schizophrenia rehabilitation, Software, Therapy, Computer-Assisted methods, Virtual Reality Exposure Therapy methods
Abstract

Cognitive difficulties are prevalent in people with diagnosis of schizophrenia and are associated with poor long-term functioning. In particular, memory, selective, divided and sustained attention and executive functions are altered by this disease. We used a Virtual Reality environment (developed via the NeuroVr2.0 software) for the rehabilitation of shifting, sustained attention and action planning functions using tasks reminiscent of daily life tasks. Test and retest showed significant differences in the assessed cognitive dimensions.

Published
2013

16. First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data

Author

Ferraro, L, Quattrone, D, La Barbera, D, La Cascia, C, Morgan, C, Kirkbride, JB, Cardno, AG, Sham, P, Tripoli, G, Sideli, L, Seminerio, F, Sartorio, C, Szoke, A, Tarricone, I, Bernardo, M, Rodriguez, V, Stilo, SA, Gayer-Anderson, C, de Haan, L, Velthorst, E, Jongsma, H, Bart, RBP, Richards, A, Arango, C, Menezez, PR, Lasalvia, A, Tosato, S, Tortelli, A, Del Ben, CM, Selten, J-P, Jones, PB, van Os, J, The WP2 EU-GEI Group, Di Forti, M, Vassos, E, Murray, RM, Adult Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, Ferraro, Laura, Quattrone, Diego, La Barbera, Daniele, La Cascia, Caterina, Morgan, Craig, Kirkbride, James B, Cardno, Alastair G, Sham, Pak, Tripoli, Giada, Sideli, Lucia, Seminerio, Fabio, Sartorio, Crocettarachele, Szoke, Andrei, Tarricone, Ilaria, Bernardo, Miquel, Rodriguez, Victoria, Stilo, Simona A, Gayer-Anderson, Charlotte, de Haan, Lieuwe, Velthorst, Eva, Jongsma, Hannah, Bart, Rutten B P, Richards, Alexander, Arango, Celso, Menezez, Paulo Rossi, Lasalvia, Antonio, Tosato, Sarah, Tortelli, Andrea, Del Ben, Cristina Marta, Selten, Jean-Paul, Jones, Peter B, van Os, Jim, Di Forti, Marta, Vassos, Evangelo, Murray, Robin M, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), and RS: MHeNs - R3 - Neuroscience

Subjects
cannabis, cannabi, Adolescent, BIPOLAR DISORDER, ADJUSTMENT, GENE-ENVIRONMENT INTERACTIONS, CLASSIFICATION, bipolar, schizophrenia, Psychiatry and Mental health, Psychotic Disorders, Risk Factors, IQ, ONSET, premorbid, Humans, Cluster Analysis, GENOME-WIDE ASSOCIATION, TRAJECTORIES, deterioration
Abstract

Cluster studies identified a subgroup of patients with psychosis whose premorbid adjustment deteriorates before the onset, which may reflect variation in genetic influence. However, other studies reported a complex relationship between distinctive patterns of cannabis use and cognitive and premorbid impairment that is worthy of consideration. We examined whether: (1) premorbid social functioning (PSF) and premorbid academic functioning (PAF) in childhood and adolescence and current intellectual quotient (IQ) define different clusters in 802 first-episode of psychosis (FEP) patients; resulting clusters vary in (2) polygenic risk scores (PRSs) for schizophrenia (SCZ_PRS), bipolar disorder (BD_PRS), major depression (MD_PRS), and IQ (IQ_PRS), and (3) patterns of cannabis use, compared to 1,263 population-based controls. Four transdiagnostic clusters emerged (BIC = 2268.5): (1) high-cognitive-functioning (n = 205), with the highest IQ (Mean = 106.1, 95% CI: 104.3, 107.9) and PAF, but low PSF. (2) Low-cognitive-functioning (n = 223), with the lowest IQ (Mean = 73.9, 95% CI: 72.2, 75.7) and PAF, but normal PSF. (3) Intermediate (n = 224) (Mean_IQ = 80.8, 95% CI: 79.1, 82.5) with low-improving PAF and PSF. 4) Deteriorating (n = 150) (Mean_IQ = 80.6, 95% CI: 78.5, 82.7), with normal-deteriorating PAF and PSF. The PRSs explained 7.9% of between-group membership. FEP had higher SCZ_PRS than controls [F(4,1319) = 20.4, P

Published
2022

17. Views of Schizophrenia Among Future Healthcare Professionals: Differences in Relation to Diagnostic Labelling, Causal Explanations, and Type of Academic Degree Program

Author

Sideli L., Sartorio C., Ferraro L., Mannino G., Giunta S., Giannone F., Seminerio F., Barone M. V., Maniaci G., Montana S., Marchese F., La Barbera D., La Cascia C., Sideli L., Sartorio C., Ferraro L., Mannino G., Giunta S., Giannone F., Seminerio F., Barone M.V., Maniaci G., Montana S., Marchese F., La Barbera D., and La Cascia C.

Subjects
schizophrenia, recovery, opinions, Settore M-PSI/08 - Psicologia Clinica, mental disorders, education, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, healthcare students, Settore MED/25 - Psichiatria, multidisciplinary care, Research Paper
Abstract

Objective: Stereotyped beliefs about schizophrenia are well-established in the society and relatively common among healthcare professionals and students. The aim of this study was to investigate the opinions about the causes, treatment, and outcome of schizophrenia among healthcare students. Method: Undergraduate nursing and psychology students completed selected items of the Opinion on Mental Illness Questionnaire after reading a clinical vignette of undiagnosed schizophrenia. Results: Students who labelled the description as schizophrenia were more pessimistic regarding full recovery from the disorder. Those who acknowledged greater relevance to biogenetic risk factors were more convinced of the efficacy of medications. Respondents’ opinions on the efficacy of psychological interventions were more positive among psychology students than among nursing students. Conclusions: The study confirmed the associations of schizophrenia labelling with prognostic pessimism and beliefs about the efficacy of pharmacological treatment among future healthcare professionals. Students’ opinions were less influenced by differences between academic degree programs. Information about current recovery rate and comprehensive care for schizophrenia may support future healthcare professionals in the relationship and the clinical management of PWS.

Published
2022

18. Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophreniaspectrum disorders: Findings from the STAR Network Depot Study

Author

Barbui C, Nosè M, Purgato M, Turrini G, Ostuzzi G, Mazzi MA, Papola D, Gastaldon C, Terlizzi S, Bertolini F, Piccoli A, Ruggeri M, De Fazio P, Magliocco F, Caroleo M, Raffaele G, D'Agostino A, Ostinelli EG, Chirico M, Cavallotti S, Lucii C, Bolognesi S, Debolini S, Pierantozzi E, Fargnoli F, Del Zanna M, Giannini A, Luccarelli L, De Capua A, Annese PM, Cerretini M, Tozzi F, Magnani N, Cardamone G, Bardicchia F, Facchi E, Soscia F, Zotos S, Biancosino B, Zonta F, Pompei F, Callegari C, Zizolfi D, Poloni N, Ielmini M, Caselli I, Giana E, Buzzi A, Diurni M, Milano A, Sani E, Calzolari R, Bortolaso P, Piccinelli M, Cazzamalli S, Alberini G, Piantanida S, Costantini C, Paronelli C, Di Caro A, Moretti V, Gozzi M, D'Ippolito C, Barbanti SV, Papalini A, Corbo M, Martinotti G, Campese O, Fiori F, Lorusso M, Di Capro L, Viceconte D, Mancini V, Suraniti F, Signorelli MSI, Rossi E, Lupoli P, Menchetti M, Terzi L, Boso M, Risaro P, De Paoli G, Catania C, Tarricone I, Caretto V, Storbini V, Emiliani R, Balzarro B, Carrà G, Bartoli F, Tabacchi T, Nava R, Bono A, Provenzi M, Brambilla G, Aspesi F, Trotta G, Tremolada M, Castagna G, Bava M, Verrengia E, Lucchi S, Oriani MG, Barchiesi M, Pacetti M, Aguglia A, Magni LR, Rossi G, Beneduce R, Tura GB, Laffranchini L, Mastromo D, Ferrato F, Restaino F, Monzani E, Porcellana M, Limosani I, Ghio L, Ferro M, Parise VF, Balletta G, Addeo L, De Vivo E, Di Benedetto R, Pinna F, Carpiniello B, Spano M, Giacomin M, Pecile D, Mattei C, Fabrici EP, Panarello S, Peresson G, Vitucci C, Bonavigo T, Perini G, Boschello F, Strizzolo S, Gardellin F, Di Giannantonio M, Moretti D, Fizzotti C, Cossetta E, Di Gregorio L, Sozzi F, Boncompagni G, La Barbera D, Colli G, Laurenzi S, Calandra C, Luca M, Crocamo C, STAR Network Depot Investigators, Bartoli F., Ostuzzi G., Crocamo C., Corbo M., D'Agostino A., Martinotti G., Ostinelli E.G., Tabacchi T., Barbui C., Carr G., Nose M., Purgato M., Turrini G., Mazzi M.A., Papola D., Gastaldon C., Terlizzi S., Bertolini F., Piccoli A., Ruggeri M., De Fazio P., Magliocco F., Caroleo M., Raffaele G., Chirico M., Cavallotti S., Lucii C., Bolognesi S., Debolini S., Pierantozzi E., Fargnoli F., Del Zanna M., Giannini A., Luccarelli L., De Capua A., Annese P.M., Cerretini M., Tozzi F., Magnani N., Cardamone G., Bardicchia F., Facchi E., Soscia F., Zotos S., Biancosino B., Zonta F., Pompei F., Callegari C., Zizolfi D., Poloni N., Ielmini M., Caselli I., Giana E., Buzzi A., Diurni M., Milano A., Sani E., Calzolari R., Bortolaso P., Piccinelli M., Cazzamalli S., Alberini G., Piantanida S., Costantini C., Paronelli C., Di Caro A., Moretti V., Gozzi M., D'Ippolito C., Barbanti S.V., Papalini A., Campese O., Fiori F., Lorusso M., Di Capro L., Viceconte D., Mancini V., Suraniti F., Signorelli M.S., Rossi E., Lupoli P., Menchetti M., Terzi L., Boso M., Risaro P., De Paoli G., Catania C., Tarricone I., Caretto V., Storbini V., Emiliani R., Balzarro B., Carra G., Nava R., Bono A., Provenzi M., Brambilla G., Aspesi F., Trotta G., Tremolada M., Castagna G., Bava M., Verrengia E., Lucchi S., Oriani M.G., Barchiesi M., Pacetti M., Aguglia A., Magni L.R., Rossi G., Beneduce R., Tura G.B., Laffranchini L., Mastromo D., Ferrato F., Restaino F., Monzani E., Porcellana M., Limosani I., Ghio L., Ferro M., Parise V.F., Balletta G., Addeo L., De Vivo E., Di Benedetto R., Pinna F., Carpiniello B., Spano M., Giacomin M., Pecile D., Mattei C., Fabrici E.P., Panarello S., Peresson G., Vitucci C., Bonavigo T., Perini G., Boschello F., Strizzolo S., Gardellin F., Di Giannantonio M., Moretti D., Fizzotti C., Cossetta E., Di Gregorio L., Sozzi F., Boncompagni G., La Barbera D., Colli G., Laurenzi S., Calandra C., Luca M., Barbui C, Nosè M, Purgato M, Turrini G, Ostuzzi G, Mazzi MA, Papola D, Gastaldon C, Terlizzi S, Bertolini F, Piccoli A, Ruggeri M, De Fazio P, Magliocco F, Caroleo M, Raffaele G, D'Agostino A, Ostinelli EG, Chirico M, Cavallotti S, Lucii C, Bolognesi S, Debolini S, Pierantozzi E, Fargnoli F, Del Zanna M, Giannini A, Luccarelli L, De Capua A, Annese PM, Cerretini M, Tozzi F, Magnani N, Cardamone G, Bardicchia F, Facchi E, Soscia F, Zotos S, Biancosino B, Zonta F, Pompei F, Callegari C, Zizolfi D, Poloni N, Ielmini M, Caselli I, Giana E, Buzzi A, Diurni M, Milano A, Sani E, Calzolari R, Bortolaso P, Piccinelli M, Cazzamalli S, Alberini G, Piantanida S, Costantini C, Paronelli C, Di Caro A, Moretti V, Gozzi M, D'Ippolito C, Barbanti SV, Papalini A, Corbo M, Martinotti G, Campese O, Fiori F, Lorusso M, Di Capro L, Viceconte D, Mancini V, Suraniti F, Signorelli MSI, Rossi E, Lupoli P, Menchetti M, Terzi L, Boso M, Risaro P, De Paoli G, Catania C, Tarricone I, Caretto V, Storbini V, Emiliani R, Balzarro B, Carrà G, Bartoli F, Tabacchi T, Nava R, Bono A, Provenzi M, Brambilla G, Aspesi F, Trotta G, Tremolada M, Castagna G, Bava M, Verrengia E, Lucchi S, Oriani MG, Barchiesi M, Pacetti M, Aguglia A, Magni LR, Rossi G, Beneduce R, Tura GB, Laffranchini L, Mastromo D, Ferrato F, Restaino F, Monzani E, Porcellana M, Limosani I, Ghio L, Ferro M, Parise VF, Balletta G, Addeo L, De Vivo E, Di Benedetto R, Pinna F, Carpiniello B, Spano M, Giacomin M, Pecile D, Mattei C, Fabrici EP, Panarello S, Peresson G, Vitucci C, Bonavigo T, Perini G, Boschello F, Strizzolo S, Gardellin F, Di Giannantonio M, Moretti D, Fizzotti C, Cossetta E, Di Gregorio L, Sozzi F, Boncompagni G, La Barbera D, Colli G, Laurenzi S, Calandra C, Luca M, Crocamo C, STAR Network Depot Investigators, Bartoli, F, Ostuzzi, G, Crocamo, C, Corbo, M, D'Agostino, A, Martinotti, G, Ostinelli, E, Tabacchi, T, Barbui, C, and Carra, G

Subjects
Aripiprazole monohydrate, Long-acting injectable antipsychotics, Paliperidone palmitate, Schizophrenia, Adult, Antipsychotic Agents, Aripiprazole, Female, Health Knowledge, Attitudes, Practice, Humans, Male, Medication Adherence, Paliperidone Palmitate, Practice Patterns, Physicians', Schizophrenic Psychology, Young Adult, Long-acting injectable antipsychotic, medicine.medical_specialty, medicine.medical_treatment, Aripiprazole monohydrate, Long-acting injectable antipsychotics, Paliperidone palmitate, Schizophrenia, Practice Patterns, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Brief Psychiatric Rating Scale, medicine, Pharmacology (medical), Antipsychotic, Settore MED/25 - Psichiatria, Practice, Physicians', business.industry, Health Knowledge, medicine.disease, 030227 psychiatry, Psychiatry and Mental health, Attitudes, Propensity score matching, Observational study, business, 030217 neurology & neurosurgery, medicine.drug, Psychopathology
Abstract

This study, based on the 'Servizi Territoriali Associati per la Ricerca' (STAR) Network Depot Study nationwide baseline data, explored whether individual symptoms severity and clusters might influence the prescription of paliperidone palmitate 1-month (PP1M) vs. aripiprazole monohydrate. The Brief Psychiatric Rating Scale (BPRS) was used to assess psychopathology and relevant symptoms clusters. Drug Attitude Inventory, 10 items, was used to test attitude towards medications. Adherence to treatments was rated according to the Kemp seven-point scale. We assessed for eligibility 451 individuals and, among them, we included 195 subjects (n = 117 who started PPM1 and n = 78 aripiprazole monohydrate). Individuals were comparable in terms of age, gender, treatment years, recent hospitalizations, previous long-acting injectable antipsychotic treatments, additional oral treatments, attitude toward drugs, medication adherence, and alcohol/substance-related comorbidities. Subjects starting PP1M presented higher BPRS overall (P = 0.009), positive (P = 0.015), and negative (P = 0.010) symptom scores compared to subjects starting aripiprazole monohydrate. Results were confirmed by appropriate regression models and propensity score matching analysis. No differences were found comparing the other BPRS subscale scores: affect, resistance, and activation. Clinicians may be more prone to prescribe PPM1, rather than aripiprazole monohydrate, to subjects showing higher overall symptom severity, including positive and negative symptoms. No additional clinical factors influenced prescribing attitudes in our sample.

Published
2020

19. Perceived public stigma towards schizophrenia among healthcare students: The relationship with diagnostic labelling and contact with people with schizophrenia

Author

Sideli L., Barone M. V., Ferraro L., Giunta S., Mannino G., Seminerio F., Sartorio C., Maniaci G., Guccione C., Giannone F., la Barbera D., la Cascia C., Sideli L., Barone M.V., Ferraro L., Giunta S., Mannino G., Seminerio F., Sartorio C., Maniaci G., Guccione C., Giannone F., la Barbera D., and la Cascia C.

Subjects
Healthcare students, Psychotic disorders, Settore M-PSI/08 - Psicologia Clinica, Perceived public stigma, Schizophrenia, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Stereotype, Settore MED/25 - Psichiatria
Abstract

Objectives This study aimed at investigating the relationship between perceived public stigma towards people with schizophrenia (PWS) and their family members in a large sample of medical and psychology students. We hypothesised that: a) schizophrenia labelling would be related to greater perceived public stigma; b) contact with PWS would be related with lower perceived stigma; c) perceived public stigma would be similar between medical and psychology students and would be higher among students attending the clinical stage compared to their pre-clinical colleagues. Methods Participants were 592 students attending either the pre-clinical or clinical stage of coursework in Medicine and Psychology, at the University of Palermo (Italy) (Tab. I). Study measures included a short socio-demographic questionnaire, the Devaluation of Consumers Scale (DCS), and the Devaluation Consumers Families Scale (DCFS). Results Students who identified schizophrenia in an unlabelled clinical description expressed greater perceived public stigma towards PWS (t = -2.895, p = 0.004) and their family members (t = -2.389, p = 0.017). A trend-level association was found between previous contact with PWS and lower perceived public stigma (t = 1.903, p = 0.058), which became significant for those students who had a more extensive contact (Mann-Whitney z = 2.063, p = 0.039). Compared to medical students, psychology students perceived greater public stigma towards PWS. No difference was observed between students at different stages of their academic coursework (Tab. II). In a multivariate linear regression model, schizophrenia labelling and degree course predicted perceived public stigma towards severe mental disorders. Conclusions This study replicated previous findings on the relationship between public stigma towards PWS, schizophrenia labelling, and contact with PWS. Perception of public stigma was similar among pre-clinical and clinical students and greater among psychology students. The findings suggest the importance of promoting a critical awareness of negative stereotypes towards schizophrenia among healthcare students, since the beginning of their coursework. In addition to correct information about schizophrenia, anti-stigma intervention should include contact with PWS who live in the community.

Published
2021

20. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study

Author

Quattrone, D, Ferraro, L, Tripoli, G, La Cascia, C, Quigley, H, Quattrone, A, Jongsma, HE, Del Peschio, S, Gatto, G, EU-GEI group, Gayer-Anderson, C, Jones, PB, Kirkbride, JB, La Barbera, D, Tarricone, I, Berardi, D, Tosato, S, Lasalvia, A, Szöke, A, Arango, C, Bernardo, M, Bobes, J, Del Ben, CM, Menezes, PR, Llorca, P-M, Santos, JL, Sanjuán, J, Tortelli, A, Velthorst, E, de Haan, L, Rutten, BPF, Lynskey, MT, Freeman, TP, Sham, PC, Cardno, AG, Vassos, E, van Os, J, Morgan, C, Reininghaus, U, Lewis, CM, Murray, RM, Di Forti, M, Adult Psychiatry, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, Quattrone, Diego [0000-0002-6051-8309], Apollo - University of Cambridge Repository, Quattrone D., Ferraro L., Tripoli G., La Cascia C., Quigley H., Quattrone A., Jongsma H.E., Del Peschio S., Gatto G., EU-GEI group, Gayer-Anderson C., Jones P.B., Kirkbride J.B., La Barbera D., Tarricone I., Berardi D., Tosato S., Lasalvia A., Szoke A., Arango C., Bernardo M., Bobes J., Del Ben C.M., Menezes P.R., Llorca P.-M., Santos J.L., Sanjuan J., Tortelli A., Velthorst E., De Haan L., Rutten B.P.F., Lynskey M.T., Freeman T.P., Sham P.C., Cardno A.G., Vassos E., Van Os J., Morgan C., Reininghaus U., Lewis C.M., Murray R.M., Di Forti M., RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R2 - Mental Health, and MUMC+: Hersen en Zenuw Centrum (3)

Subjects
Marijuana Abuse, IMPACT, Poison control, Cannabis use, cannabis-associated psychosis, 0302 clinical medicine, SCHIZOPHRENIA, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, health care economics and organizations, Applied Psychology, RISK, OUTCOMES, biology, Human factors and ergonomics, psychopathology, first episode psychosis, psychotic experiences, symptom dimensions, 3. Good health, Psychiatry and Mental health, Schizophrenia, HEALTH, Psychopathology, Psychosis, medicine.medical_specialty, DISORDERS, education, 03 medical and health sciences, Injury prevention, medicine, Humans, Psychiatry, ABUSE, Settore MED/25 - Psichiatria, SUBSTANCE USE, METAANALYSIS, Cannabis, business.industry, Case-control study, Original Articles, medicine.disease, biology.organism_classification, 030227 psychiatry, psychotic experience, Psychotic Disorders, first episode psychosi, Case-Control Studies, ONSET, Gene-Environment Interaction, business, cannabis-associated psychosi, 030217 neurology & neurosurgery
Abstract

The work was supported by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College Hospital NHS Foundation Trust to DQ; DFG Heisenberg professorship (no. 389624707) to UR. National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0., Quattrone, D., Ferraro, L., Tripoli, G., La Cascia, C., Quigley, H., Quattrone, A., Jongsma, H.E., Del Peschio, S., Gatto, G., Gayer-Anderson, C., Jones, P.B., Kirkbride, J.B., La Barbera, D., Tarricone, I., Berardi, D., Tosato, S., Lasalvia, A., Szöke, A., Arango, C., Bernardo, M., Bobes, J., Del Ben, C.M., Menezes, P.R., Llorca, P.-M., Santos, J.L., Sanjuán, J., Tortelli, A., Velthorst, E., De Haan, L., Rutten, B.P.F., Lynskey, M.T., Freeman, T.P., Sham, P.C., Cardno, A.G., Vassos, E., Van Os, J., Morgan, C., Reininghaus, U., Lewis, C.M., Murray, R.M., Di Forti, M.

Published
2020

21. Use of multiple Polygenic Risk Scores for distinguishing Schizophrenia-spectrum disorder and Affective psychosis categories; the EUGEI study

Author

Robin M. Murray, Hannah E. Jongsma, Di Forti M, Evangelos Vassos, van os J, Manuel Arrojo, Jean-Paul Selten, Edoardo Spinazzola, Julio Bobes, Laura Ferraro, Ilaria Tarricone, Alameda L, La Barbera D, Pak C. Sham, Rodriguez, Peter B. Jones, Eva Velthorst, Giada Tripoli, Pierre-Michel Llorca, Alexander Richards, C. Arango, Stéphane Jamain, Elena Bonora, Simona A. Stilo, La Cascia C, Antonio Lasalvia, Craig Morgan, M O'Donovan, Diego Quattrone, Charlotte Gayer-Anderson, de Haan L, Miguel Bernardo, Trotta G, Bart P. F. Rutten, Sarah Tosato, and James B. Kirkbride

Subjects
Affective psychosis, Psychosis, Schizophrenia, business.industry, medicine, Polygenic risk score, Psychotic depression, Bipolar disorder, medicine.disease, business, Depression (differential diagnoses), Clinical psychology, Multinomial logistic regression
Abstract

Schizophrenia (SZ), Bipolar Disorder (BD) and Depression (D) run in families. This susceptibility is partly due to hundreds or thousands of common genetic variants, each conferring a fractional risk. The cumulative effects of the associated variants can be summarised as a polygenic risk score (PRS). Using data from the EUGEI case-control study, we aimed to test whether PRSs for three major psychiatric disorders (SZ, BD, D) and for intelligent quotient (IQ) as a neurodevelopmental proxy, can discriminate affective psychosis (AP) from schizophrenia-spectrum disorder (SSD). Participants (573 cases, 1005 controls) of european ancestry from 17 sites as part of the EUGEI study were successfully genotyped following standard quality control procedures. Using standardised PRS for SZ, BD, D, and IQ built from the latest available summary statistics, we performed simple or multinomial logistic regression models adjusted for 10 principal components for the different clinical comparisons. In case-control comparisons PRS-SZ, PRS-BD and PRS-D distributed differentially across psychotic subcategories. In case-case comparison, both PRS-SZ (OR=0.7, 95 %CI 0.53-0.92) and PRS-D (OR=1.29, 95%CI 1.05-1.6) differentiated global AP from SSD; and within AP categories, only PRS-SZ differentiated BD from psychotic depression (OR=2.38, 95%CI 1.32-4.29). Combining PRS for severe psychiatric disorders in prediction models for psychosis phenotypes can increase discriminative ability and improve our understanding of these phenotypes. Our results point towards potential usefulness of PRSs for diagnostic prediction in specific populations such as high-risk or early psychosis phases.

Published
2021

22. Schizophrenia polygenic risk score and cannabis use modify psychosis expression in first episode psychosis patients and population controls

Author

Peter B. Jones, Robin M. Murray, Jose Luis Santos, Di Forti M, Ilaria Tarricone, Tom P. Freeman, Bart P. F. Rutten, Sarah Tosato, Giada Tripoli, Craig Morgan, Elena Bonora, James B. Kirkbride, Cathryn M. Lewis, Celso Arango, Pak C. Sham, Charlotte Gayer-Anderson, Julio Bobes, Hannah E. Jongsma, Paolo Marino, Ulrich Reininghaus, Rodriguez, Alastair G. Cardno, van os J, Eva Velthorst, Evangelos Vassos, Michael T. Lynskey, La Barbera D, Miguel Bernardo, Paulo Rossi Menezes, Andrea Tortelli, Laura Ferraro, de Haan L, Pierre-Michel Llorca, Alexander Richards, Del Ben Cm, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, La Cascia C, Julio Sanjuán, and M O'Donovan

Subjects
education.field_of_study, Psychosis, business.industry, Population, Cannabis use, medicine.disease, 030227 psychiatry, 03 medical and health sciences, 0302 clinical medicine, Environmental risk, Schizophrenia, First episode psychosis, Medicine, Polygenic risk score, In patient, business, education, 030217 neurology & neurosurgery, Clinical psychology
Abstract

BackgroundDiagnostic categories within the psychosis spectrum are widely used in clinical practice, however psychosis may occur on a continuum. Therefore, we explored whether the continuous distribution of psychotic symptoms across categories is a function of genetic as well as environmental risk factors, such as polygenic risk scores (PRSs) and cannabis use.MethodsAs part of the EU-GEI study, we genotyped first episode psychosis patients (FEP) and population controls, for whom transdiagnostic dimensions of psychotic symptoms or experiences were generated using item response bi-factor modelling. Linear regression was used, separately in patients and controls, to test the associations between these dimensions and schizophrenia (SZ) PRSs, as well as the combined effect of SZ-PRS and cannabis use on the positive symptom/experience dimensions.ResultsSZ-PRS was associated with negative (B=0.18; 95%CI 0.03 to 0.34) and positive (B=0.19; 95%CI 0.03 to 0.36) symptom dimensions in 617 FEP, and with all the psychotic experience dimensions in 979 controls. The putative effect of SZ-PRS on either symptom or experience dimensions was of a small magnitude. Cannabis use was additionally associated with the positive dimensions both in FEP (B=0.31; 95%CI 0.11 to 0.52) and in controls (B=0.26; 95%CI 0.06 to 0.46), independently from SZ-PRS.ConclusionsWe report two validators to the latent dimensional structure of psychosis. SZ risk variants and cannabis use independently map onto specific dimensions, contributing to variation across the psychosis continuum. Findings support the hypothesis that psychotic experiences have similar biological substrates as clinical disorders.

Published
2019

23. Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use

Author

Ferraro L, La Cascia C, Quattrone D, Sideli L, Matranga D, Capuccio V, Tripoli G, Gayer-Anderson C, Morgan C, Sami M, Sham P, de Haan L, Velthorst E, Jongsma H, Kirkbride J, Rutten B, Richards A, Roldan L, Arango C, Bernardo M, Bobes J, Sanjuan J, Santos J, Arrojo M, Tarricone I, Tortelli A, Szoke A, Del-Ben C, Selten J, Lynskey M, Jones P, Van Os J, La Barbera D, Murray R, Di Forti M, WP2 EU-GEI GROUP, Jones, Peter [0000-0002-0387-880X], and Apollo - University of Cambridge Repository

Subjects
cognition, Adult, Male, education, Adolescent, Intelligence, preillness, Comorbidity, Middle Aged, schizophrenia, sociability, Psychosocial Functioning, Young Adult, Psychotic Disorders, Case-Control Studies, Humans, Female, Marijuana Use, marijuana, Social Adjustment
Abstract

Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic patients who had ever used cannabis compared to patients without any history of use. We did not expect such differences in controls. In both patients and controls, IQ was 3 points higher among occasional-users than in never-users (mean difference [Mdiff] = 2.9, 95% CI = [1.2, 4.7]). Both cases and control daily-users had lower AF compared to occasional (Mdiff = -0.3, 95% CI = [-0.5; -0.2]) and never-users (Mdiff = -0.4, 95% CI = [-0.6; -0.2]). Finally, patient occasional (Mdiff = 0.3, 95% CI = [0.1; 0.5]) and daily-users (Mdiff = 0.4, 95% CI = [0.2; 0.6]) had better SF than their never-using counterparts. This difference was not present in controls (Fgroup*frequency(2, 2205) = 4.995, P = .007). Our findings suggest that the better premorbid social functioning of FEP with a history of cannabis use may have contributed to their likelihood to begin using cannabis, exposing them to its reported risk-increasing effects for Psychotic Disorders. © The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.

Published
2019
Full Text
View/download PDF

24. Virtual reality environments to rehabilitation attention deficits in schizophrenic patients

Author

La Paglia, F., Caterina LA CASCIA, Rizzo, R., Sanna, M., Cangialosi, F., Sideli, L., Francomano, A., Riva, G., La Barbera, D., LA PAGLIA, F, LA CASCIA, C, RIZZO, R, SANNA, M, CANGIALOSI, F, SIDELI, L, FRANCOMANO, A, RIVA, G, LA BARBERA, D, LA PAGLIA, F., LA CASCIA, C., RIZZO, R., SANNA, M., SIDELI, L., FRANCOMANO, A., RIVA, G., and LA BARBERA, D.

Subjects
Settore M-PSI/08 - Psicologia Clinica, Cognitive rehabilitation, Schizophrenia, Sustained attention, Virtual reality, Neuroscience (miscellaneous), Computer Science (miscellaneous), Rehabilitation, Psychology (miscellaneous), Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Settore M-PSI/01 - PSICOLOGIA GENERALE, Virtual Reality, Schizophrenia, Cognitive Rehabilitation, Sustained Attention, Settore MED/25 - Psichiatria
Abstract

Cognitive dysfunction is a core feature of schizophrenia. Patients with schizophrenia shown perform poorly on tasks that require vigilance or sustained attention. Patients with more pronounced attention deficits are least likely to acquire skills in psychosocial programs as the attention problems makes it difficult for them to process the information given in groups, and they may not be able to sustain attention for the session duration. The study aimed to develop a Virtual Reality cognitive training to improve the selective, divide and sustained attention. Specifically, we developed, via the NeuroVr 2.0 software, three different virtual environments with the hierarchical sequences of tasks. The study included two clinical samples of patients suffering from schizophrenia disorder: experimental group (9 patients) treated with pharmacological therapy and Virtual Reality cognitive training (10 weekly individual sessions); control group (6 patients) received pharmacological therapy and Integrated Psychological Treatment. Before and after training

25. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations

Author

Rosana Shuhama, Gonzalo López, Viviana Storbini, Tolga Binbay, Ma Soledad Olmeda, Maria Calem, Marina Mihaljevic, Christos Pantelis, Halis Ulaş, Eva Velthorst, Jeroen Decoster, J. Malte Bumb, Ruud van Winkel, E. Cem Atbasoglu, Wolfgang Viechtbauer, Mirella Ruggeri, Erich Studerus, Daniele La Barbera, Domenico Berardi, Anita Riecher-Rössler, Stefan Borgwardt, Elsje van der Ven, Charlotte Rapp, Desiree Hilboll, Mark van der Gaag, Chiara Bonetto, Marie-Odile Krebs, Silvia Tenan, Monika Schlögelhofer, Robin M. Murray, Caterina La Cascia, Philip McGuire, Simona A. Stilo, Desmond Campbell, Fabienne Harrisberger, Teresa Sánchez, Catherine Derom, Franck Schürhoff, Philippe Delespaul, Jose Luis Santos, Emilio Sánchez, Stephan Ruhrmann, Luigi Rocco Chiri, Sabrina Cruz, Handan Noyan, Dominika Julkowski, Celso Arango, Merete Nordentoft, Stacey S. Cherny, Anne-Marie Galliot, Daniella van Dam, María Pouso, Asier Urruela Mora, G. Paul Amminger, Enrique García Bernardo, Ahmet Ayer, Tijana Mirjanic, Andrei Szöke, Anna Walter, Antonio Lasalvia, Isla Humphreys, Flora Frijda, Lieuwe de Haan, Neus Barrantes-Vidal, Nigel Williams, Burçin Cihan, Matthew J. Kempton, Ceren Akdeniz, Tamar Kraan, Andrea Tortelli, Barnaby Nelson, Marta Di Forti, Angelo Fioritti, Pedro Cuadrado, Eylem Sahin Cankurtaran, Emanuel Schwarz, Andreas Meyer-Lindenberg, Ilaria Tarricone, Laura Ferraro, Dan Rujescu, Anne-Marie Tronche, Laura Roldan, Bibiana Cabrera, Alp Üçok, Craig Morgan, Julio Sanjuán, Mauro Braca, Julio Bobes, Eric Y.H. Chen, Michael Conlon O'Donovan, Peter Holmans, Harald N. Aschauer, Sarah Ittig, Covadonga Martínez, Iris Lasser, Emiliano González, Aitziber Emaldi Cirión, Rachele Sartorio, F. Seminerio, Rodrigo A. Bressan, Ulrich Reininghaus, Elisa Brietzke, François Bourque, G Tripoli, Inez Myin-Germeys, Aziz Ferchiou, Gemma Modinos, Grégoire Baudin, Fabienne Soguel-Dit-Piquard, Cristina Marta Del-Ben, Gabriele Sachs, Elçin Akturan, Manuel Arrojo, Thomas R. Kwapil, Alice Mulè, Eva Mª Díaz Mesa, Federico Chierzi, Köksal Alptekin, Floor J. van der Meer, Pak C. Sham, Jim van Os, Adanna Onyejiaka, Mara Parellada, Bart P. F. Rutten, Jeanne Vilain, Michael John Owen, Sarah Tosato, Haldan Soygür, A.M. Marinaro, Stefania Tognin, Evert Thiery, Cathrin Rohleder, Mary Cannon, Miaoxin Li, F. Markus Leweke, Marc De Hert, Marta Rapado, Maria Gabriella Minenna, Pierre-Michel Llorca, Alexander Richards, Stéphane Jamain, Elles Messchaert, Nadja P. Maric, Semra Ulusoy, Elisa Ira, Peter G. Jones, Paulo Rossi Menezes, Patrick D. McGorry, Bernadette Winklbaur, Stephanie Beards, Nadine Burger, Güvem Gümüş-Akay, Marion Leboyer, James B. Kirkbride, Sinan Guloksuz, Ary Gadelha, E. Bulzacka, Carlos M. Romeo-Casabona, Gülşah Karadayı, Jean-Paul Selten, José Juan Rodríguez Solano, Kathryn Hubbard, Estela Jiménez, Thomas Charpeaud, Nikos C. Stefanis, Lucia Sideli, Miguel Bernardo, Jean-Romain Richard, Ivonne Donegani, Marco Seri, Lucia Valmaggia, Julia Paruch, Catherine van Zelst, Meram Can Saka, Heike Tost, Renata Smieskova, Thomas Marcacci, Nicholas John Craddock, Berna Binnur Akdede, Joachim Klosterkötter, Richard Bruggeman, Charlotte Gayer-Anderson, Sanja Andric, Elena Bonora, Angel Carracedo, Hasan Karadağ, Paula Cristobal, ANS - Amsterdam Neuroscience, Adult Psychiatry, Graduate School, Perceptual and Cognitive Neuroscience (PCN), Maastricht Univ, Kings Coll London, Mondriaan Mental Hlth Trust, Univ Groningen, Cardiff Univ, Cent Inst Mental Hlth, Dokuz Eylul Univ, Istanbul Univ, Ankara Univ, Yale Univ, Middle E Tech Univ, Diskapi YB Res & Training Hosp, Turkish Federat Schizophrenia Assoc, Ataturk Training & Res Hosp, Manisa Mental Hlth Hosp, Univ Complutense, Univ Barcelona, Univ Valencia, Univ Oviedo, Univ Santiago de Compostela, Hosp Virgen de la Luz, Hosp Univ Infanta Leonor Hosp Virgen Torre, Hosp Clin Univ, Hosp Psiquiatr Conxo, Univ Amsterdam, Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Parnassia Psychiat Inst, Rivierduinen Psychiat Inst, Grp Hosp Mondor, Hop Henri Mondor, Univ Paris Est, Fdn Fondamental, CMP B CHU, Univ Auvergne, EPS Maison Blanche, UPC KU Leuven, UPC, Katholieke Univ Leuven, Assoc Sci Res Multiple Births, Univ Ghent, Univ Athens, Med Univ Vienna, Psychiat Univ Clin Basel, Univ Cologne, Univ Hong Kong, Univ Basque Country, Univ Zaragoza, Univ Cambridge, UCL, Royal Coll Surgeons Ireland, Univ Munich, Univ Bologna, Local Hlth Trust, Univ Palermo, P Giaccone Gen Hosp, Univ Melbourne, Universidade de São Paulo (USP), Univ Verona, Copenhagen Univ Hosp, Univ Paris 05, Univ Autonoma Barcelona, St Pere Claver Fundacio Sanitaria, Univ N Carolina, CIBERSAM, Universidade Federal de São Paulo (UNIFESP), Univ Belgrade, van Os J, Rutten BP, Myin-Germeys I, Delespaul P, Viechtbauer W, van Zelst C, Bruggeman R, Reininghaus U, Morgan C, Murray RM, Di Forti M, McGuire P, Valmaggia LR, Kempton MJ, Gayer-Anderson C, Hubbard K, Beards S, Stilo SA, Onyejiaka A, Bourque F, Modinos G, Tognin S, Calem M, O'Donovan MC, Owen MJ, Holmans P, Williams N, Craddock N, Richards A, Humphreys I, Meyer-Lindenberg A, Leweke FM, Tost H, Akdeniz C, Rohleder C, Bumb JM, Schwarz E, Alptekin K, Üçok A, Saka MC, Atbaşoğlu EC, Gülöksüz S, Gumus-Akay G, Cihan B, Karadağ H, Soygür H, Cankurtaran EŞ, Ulusoy S, Akdede B, Binbay T, Ayer A, Noyan H, Karadayı G, Akturan E, Ulaş H, Arango C, Parellada M, Bernardo M, Sanjuán J, Bobes J, Arrojo M, Santos JL, Cuadrado P, Rodríguez Solano JJ, Carracedo A, García Bernardo E, Roldán L, López G, Cabrera B, Cruz S, Díaz Mesa EM, Pouso M, Jiménez E, Sánchez T, Rapado M, González E, Martínez C, Sánchez E, Olmeda MS, de Haan L, Velthorst E, van der Gaag M, Selten JP, van Dam D, van der Ven E, van der Meer F, Messchaert E, Kraan T, Burger N, Leboyer M, Szoke A, Schürhoff F, Llorca PM, Jamain S, Tortelli A, Frijda F, Vilain J, Galliot AM, Baudin G, Ferchiou A, Richard JR, Bulzacka E, Charpeaud T, Tronche AM, De Hert M, van Winkel R, Decoster J, Derom C, Thiery E, Stefanis NC, Sachs G, Aschauer H, Lasser I, Winklbaur B, Schlögelhofer M, Riecher-Rössler A, Borgwardt S, Walter A, Harrisberger F, Smieskova R, Rapp C, Ittig S, Soguel-dit-Piquard F, Studerus E, Klosterkötter J, Ruhrmann S, Paruch J, Julkowski D, Hilboll D, Sham PC, Cherny SS, Chen EY, Campbell DD, Li M, Romeo-Casabona CM, Emaldi Cirión A, Urruela Mora A, Jones P, Kirkbride J, Cannon M, Rujescu D, Tarricone I, Berardi D, Bonora E, Seri M, Marcacci T, Chiri L, Chierzi F, Storbini V, Braca M, Minenna MG, Donegani I, Fioritti A, La Barbera D, La Cascia CE, Mulè A, Sideli L, Sartorio R, Ferraro L, Tripoli G, Seminerio F, Marinaro AM, McGorry P, Nelson B, Amminger GP, Pantelis C, Menezes PR, Del-Ben CM, Gallo Tenan SH, Shuhama R, Ruggeri M, Tosato S, Lasalvia A, Bonetto C, Ira E, Nordentoft M, Krebs MO, Barrantes-Vidal N, Cristóbal P, Kwapil TR, Brietzke E, Bressan RA, Gadelha A, Maric NP, Andric S, Mihaljevic M, Mirjanic T, Clinical Psychology, EMGO+ - Mental Health, Van Os, J., Rutten, B., Myin Germeys, I., Delespaul, P., Viechtbauer, W., Van Zelst, C., Bruggeman, R., Reininghaus, U., Morgan, C., Murray, R., Di Forti, M., Mcguire, P., Valmaggia, L., Kempton, M., Gayer Anderson, C., Hubbard, K., Beards, S., Stilo, S., Onyejiaka, A., Bourque, F., Modinos, G., Tognin, S., Calem, M., O'Donovan, M., Owen, M., Holmans, P., Williams, N., Craddock, N., Richards, A., Humphreys, I., Meyer Lindenberg, A., Leweke, F., Tost, H., Akdeniz, C., Rohleder, C., Bumb, J., Schwarz, E., Alptekin, K., Üçok, A., Saka, M., Atbagoǧlu, E., Gülöksüz, S., Gumus Akay, G., Cihan, B., Karadaǧ, H., Soygür, H., Cankurtaran, E., Ulusoy, S., Akdede, B., Binbay, T., Ayer, A., Noyan, H., Karadayi, G., Akturan, E., Ulaş, H., Arango, C., Parellada, M., Bernardo, M., Sanjuán, J., Bobes, J., Arrojo, M., Santos, J., Cuadrado, P., Solano, J., Carracedo, A., Bernardo, E., Roldán, L., López, G., Cabrera, B., Cruz, S., Mesa, E., Pouso, M., Jiménez, E., Sánchez, T., Rapado, M., González, E., Martínez, C., Sánchez, E., Olmeda, M., De Haan, L., Velthorst, E., Van Der Gaag, M., Selten, J., Van Dam, D., Van Der Ven, E., Van Der Meer, F., Messchaert, E., Kraan, T., Burger, N., Leboyer, M., Szoke, A., Schürhoff, F., Llorca, P., Jamain, S., Tortelli, A., Frijda, F., Vilain, J., Galliot, A., Baudin, G., Ferchiou, A., Richard, J., Bulzacka, E., Charpeaud, T., Tronche, A., De Hert, M., Van Winkel, R., Decoster, J., Derom, C., Thiery, E., Stefanis, N., Sachs, G., Aschauer, H., Lasser, I., Winklbaur, B., Schlögelhofer, M., Riecher Rössler, A., Borgwardt, S., Walter, A., Harrisberger, F., Smieskova, R., Rapp, C., Ittig, S., Soguel Dit Piquard, F., Studerus, E., Klosterkötter, J., Ruhrmann, S., Paruch, J., Julkowski, D., Hilboll, D., Sham, P., Cherny, S., Chen, E., Campbell, D., Li, M., Romeo Casabona, C., Cirión, A., Mora, A., Jones, P., Kirkbride, J., Cannon, M., Rujescu, D., Tarricone, I., Berardi, D., Bonora, E., Seri, M., Marcacci, T., Chiri, L., Chierzi, F., Storbini, V., Braca, M., Minenna, M., Donegani, I., Fioritti, A., LA BARBERA, D., LA CASCIA, C., Mulè, A., Sideli, L., Sartorio, C., Ferraro, L., Tripoli, G., Seminerio, F., Marinaro, A., Mcgorry, P., Nelson, B., Amminger, G., Pantelis, C., Menezes, P., Del Ben, C., Tenan, S., Shuhama, R., Ruggeri, M., Tosato, S., Lasalvia, A., Bonetto, C., Ira, E., Nordentoft, M., Krebs, M., Barrantes Vidal, N., Cristóbal, P., Kwapil, T., Brietzke, E., Bressan, R., Gadelha, A., Maric, N., Andric, S., Mihaljevic, M., Mirjanic, T., Psychiatrie & Neuropsychologie, Promovendi MHN, and RS: MHeNs - R2 - Mental Health

Subjects
URBANICITY, Schizophrenia (object-oriented programming), CHILDHOOD, Genome-wide association study, VARIANTS, Social Environment, psychosi, 03 medical and health sciences, 0302 clinical medicine, PSYCHOSIS, epidemiology, gene-environment interaction, genetics, psychosis, schizophrenia, SDG 3 - Good Health and Well-being, RISK-FACTOR, Settore M-PSI/08 - Psicologia Clinica, Genetic variation, Humans, Genetic Predisposition to Disease, GENOME-WIDE ASSOCIATION, Gene, Settore MED/25 - Psichiatria, METAANALYSIS, Scale (chemistry), Psychosis, Genetic variants, Environment and Schizophrenia Invited, CANNABIS USE, 3. Good health, 030227 psychiatry, Psychiatry and Mental health, Evolutionary biology, Identification (biology), Schizophrenic Psychology, Population Risk, genetic, Psychology, FOLLOW-UP, 030217 neurology & neurosurgery, FUTURE-DIRECTIONS, Clinical psychology
Abstract

European Community Recent years have seen considerable progress in epidemiological and molecular genetic research into environmental and genetic factors in schizophrenia, but methodological uncertainties remain with regard to validating environmental exposures, and the population risk conferred by individual molecular genetic variants is small. There are now also a limited number of studies that have investigated molecular genetic candidate gene-environment interactions (G x E), however, so far, thorough replication of findings is rare and G x E research still faces several conceptual and methodological challenges. in this article, we aim to review these recent developments and illustrate how integrated, large-scale investigations may overcome contemporary challenges in G x E research, drawing on the example of a large, international, multi-center study into the identification and translational application of G x E in schizophrenia. While such investigations are now well underway, new challenges emerge for G x E research from late-breaking evidence that genetic variation and environmental exposures are, to a significant degree, shared across a range of psychiatric disorders, with potential overlap in phenotype. Maastricht Univ, Med Ctr, Dept Psychiat & Neuropsychol, Sch Mental Hlth & Neurosci,South Limburg Mental H, NL-6200 MD Maastricht, Netherlands Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London WC2R 2LS, England Mondriaan Mental Hlth Trust, Maastricht, Heerlen, Netherlands Univ Groningen, Univ Med Ctr Groningen, Rob Giel Clin Res, Univ Ctr Psychiat, Groningen, Netherlands Kings Coll London, Inst Psychiat, Dept Hlth Serv & Populat Res, London WC2R 2LS, England Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England Cardiff Univ, MRC, Ctr Neuropsychiat Genet, Cardiff CF10 3AX, S Glam, Wales Cent Inst Mental Hlth, Dept Psychiat & Psychotherapy, Mannheim, Germany Dokuz Eylul Univ, Sch Med, Dept Psychiat, Konak, Turkey Istanbul Univ, Istanbul Fac Med, Dept Psychiat, Psychot Disorders Res Unit, Istanbul, Turkey Ankara Univ, Sch Med, Dept Psychiat, Cebeci Hosp, TR-06100 Ankara, Turkey Ankara Univ, Brain Res Ctr, TR-06100 Ankara, Turkey Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA Middle E Tech Univ, Dept Psychol, TR-06531 Ankara, Turkey Diskapi YB Res & Training Hosp, Ankara, Turkey Turkish Federat Schizophrenia Assoc, Ankara, Turkey Ataturk Training & Res Hosp, Psychiat Clin, Ankara, Turkey Manisa Mental Hlth Hosp, Manisa, Turkey Istanbul Univ, Expt Med Res Inst, Dept Adv Neurol Sci, Istanbul Fac Med, Istanbul, Turkey Univ Complutense, IiSGM CIBERSAM, Dept Child & Adolescent Psychiat, Hosp Gen Univ Gregorio Maranon,Sch Med, E-28040 Madrid, Spain Univ Barcelona, Dept Psychiat, Hosp Clin, IDIBAPS,Ctr Invest Biomed Red Salud Mental CIBERS, Barcelona, Spain Univ Valencia, Sch Med, Dept Psychiat, Ctr Invest Biomed Red Salud Mental CIBERSAM, Valencia, Spain Univ Oviedo, Sch Med, Dept Med,Psychiat Area, Ctr Invest Biomed Red Salud Mental CIBERSAM, Oviedo, Spain Univ Santiago de Compostela, Dept Mental Hlth & Drug Addit Assistance, Hlth Serv Galicia,Psychiat Genet Grp IDIS, Hosp Clin,Ctr Invest Biomedica Red Salud Mental C, Santiago de Compostela 15706, Spain Hosp Virgen de la Luz, Serv Psiquiat, Dept Psychiat, Cuenca, Spain Hosp Univ Infanta Leonor Hosp Virgen Torre, Villa de Vallecas Mental Hlth Ctr, Villa de Vallecas Mental Hlth Dept, Madrid, Spain Hosp Univ Infanta Leonor Hosp Virgen Torre, Puente de Vallecas Mental Hlth Dept, Ctr Salud Mental Puente Vallecas, Madrid, Spain Hosp Clin Univ, Fdn Publ Galega Med Xenomica, Santiago de Compostela, Spain Univ Complutense, Sch Med, Hosp Gen Univ Gregorio Maranon, Dept Psychiat, E-28040 Madrid, Spain Hosp Psiquiatr Conxo, Santiago de Compostela, Spain Univ Amsterdam, Acad Med Ctr, Early Psychosis Sect, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands EMGO Inst Hlth & Care Res, Amsterdam, Netherlands Parnassia Psychiat Inst, Dept Psychosis Res, the Hague, Netherlands Rivierduinen Psychiat Inst, Leiden, Netherlands Grp Hosp Mondor, AP HP, Creteil, France Hop Henri Mondor, INSERM, U955, Equipe 15, F-94010 Creteil, France Univ Paris Est, Fac Med, Creteil, France Fdn Fondamental, Creteil, France CMP B CHU, F-63003 Clermont Ferrand 1, France Univ Auvergne, EA 7280, Clermont Ferrand, France EPS Maison Blanche, Paris, France UPC KU Leuven, Dept Neurosci, UPC, Kortenberg, Belgium UPC, Dept Neurosci, Res Grp Psychiat, Leuven, Belgium Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Human Genet, Leuven, Belgium Assoc Sci Res Multiple Births, Ghent, Belgium Univ Ghent, Dept Neurol, Ghent Univ Hosp, B-9000 Ghent, Belgium Univ Athens, Sch Med, Eginit Hosp, Athens 11528, Greece Med Univ Vienna, Dept Psychiat & Psychotherapy, Vienna, Austria Psychiat Univ Clin Basel, Ctr Gender Res & Early Detect, Basel, Switzerland Psychiat Univ Clin Basel, Diagnost & Crisis Intervent Ctr, Basel, Switzerland Univ Cologne, Dept Psychiat & Psychotherapy, D-50931 Cologne, Germany Univ Hong Kong, Li Ka Shing Fac Med, Ctr Genom Sci, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China Univ Basque Country, Univ Deusto, Interuniv Chair Law & Human Genome Prov Govt Bisk, Bilbao, Bizkaia, Spain Univ Zaragoza, Zaragoza, Spain Univ Cambridge, Dept Psychiat, Cambridge, England UCL, Div Psychiat, London, England Royal Coll Surgeons Ireland, Beaumont Hosp, Educ & Res Ctr, Dept Psychiat, Dublin 9, Ireland Univ Munich, Dept Psychiat, Div Mol & Clin Neurobiol, Munich, Germany Univ Bologna, Alma Mater Studiorium, Psychiat Unit, Dept Med & Surg Sci, Bologna, Italy Univ Bologna, Alma Mater Studiorium, Genet Unit, Dept Med & Surg Sci, Bologna, Italy Local Hlth Trust, Dept Mental Hlth & Pathol Addict, Bologna, Italy Univ Palermo, Sect Psychiat, Dept Expt Biomed & Clin Neurosci, Palermo, Italy P Giaccone Gen Hosp, Unit Psychiat, Palermo, Italy Univ Melbourne, Ctr Youth Mental Hlth, Parkville, Vic 3052, Australia Univ Melbourne, Melbourne Neuropsychiat Ctr, Carlton, Vic, Australia Univ São Paulo, Fac Med, Dept Med Prevent, BR-01246903 São Paulo, Brazil Univ São Paulo, Nucleo Pesquina Saude Mental Populac, São Paulo, Brazil Univ São Paulo, Fac Med Ribeirao Preto, Dept Neurociencias & Ciencias Comportamento, BR-14049 Ribeirao Preto, Brazil Univ Verona, Sect Psychiat, Dept Publ Hlth & Community Med, I-37100 Verona, Italy Copenhagen Univ Hosp, Res Unit, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark Univ Paris 05, Fac Med, Serv Hosp Univ, Hop St Anne, Paris, France Univ Autonoma Barcelona, Dept Psicol Clin & Salut, E-08193 Barcelona, Spain St Pere Claver Fundacio Sanitaria, Dept Salut Mental, Barcelona, Spain Univ N Carolina, Dept Psychol, Greensboro, NC 27412 USA CIBERSAM, Spanish Mental Hlth Res Network, Barcelona, Spain Universidade Federal de São Paulo, Dept Psychiat, PRISMA Early Intervent Program, São Paulo, Brazil Univ Belgrade, Sch Med, Beograd, Serbia Universidade Federal de São Paulo, Dept Psychiat, PRISMA Early Intervent Program, São Paulo, Brazil European Community: HEALTH-F2-2009-241909 Web of Science

Published
2014

26. Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study

Author

D'Agostino, Armando, Aguglia, Andrea, Barbui, Corrado, Bartoli, Francesco, Carrà, Giuseppe, Cavallotti, Simone, Chirico, Margherita, Ostinelli, Edoardo G, Zangani, Caroline, Martinotti, Giovanni, Ostuzzi, Giovanni, Bertolini, Federico, Calandra, Carmela, Callegari, Camilla, D’Agostino, Armando, Lucii, Claudio, Mastromo, Daniele, Moretti, Daniele, Monzani, Emiliano, Porcellana, Matteo, Prestia, Davide, Nose, Michela, Purgato, Marianna, Turrini, Giulia, Mazzi, Maria, Angela, Papola, Davide, Gastaldon, Chiara, Terlizzi, Samira, Piccoli, Alberto, Ruggeri, Mirella, De Fazio, Pasquale, Magliocco, Fabio, Caroleo, Mariarita, Raffaele, Gaetano, Ostinelli, Edoardo, Giuseppe, Bolognesi, Simone, Debolini, Sara, Pierantozzi, Elisa, Fargnoli, Francesco, Del Zanna, Maria, Giannini, Alessandra, Luccarelli, Livia, De Capua, Alberto, Annese, Pasqua, Maria, Cerretini, Massimiliano, Tozzi, Fiorella, Magnani, Nadia, Cardamone, Giuseppe, Bardicchia, Francesco, Facchi, Edvige, Soscia, Federica, Zotos, Spyridon, Biancosino, Bruno, Zonta, Filippo, Pompei, Francesco, Zizolfi, Daniele, Ielmini, Marta, Caselli, Ivano, Giana, Edoardo, Buzzi, Aldo, Emanuele, Diurni, Marcello, Milano, Anna, Sani, Emanuele, Calzolari, Roberta, Bortolaso, Paola, Piccinelli, Marco, Cazzamalli, Sara, Caterina, Alberini, Gabro, Piantanida, Silvia, Costantini, Chiara, Paronelli, Chiara, Di Caro, Angela, Moretti, Valentina, Gozzi, Mauro, D'Ippolito, Chiara, Barbanti Silva, Veronica, Papalini, Alessandro, Corbo, Mariangela, Campese, Ornella, Fiori, Federica, Lorusso, Marco, Di Capro, Lucia, Viceconte, Daniela, Mancini, Valerio, Suraniti, Francesco, Signorelli, Maria, Salvina, Rossi, Eugenio, Lupoli, Pasqualino, Menchetti, Marco, Terzi, Laura, Boso, Marianna, Risaro, Paolo, De Paoli, Giuseppe, Catania, Cristina, Tarricone, Ilaria, Caretto, Valentina, Storbini, Viviana, Emiliani, Roberta, Balzarro, Beatrice, Carra, Giuseppe, Tabacchi, Tommaso, Nava, Roberto, Bono, Adele, Provenzi, Milena, Brambilla, Giulia, Aspesi, Flora, Tremolada, Martina, Castagna, Gloria, Bava, Mattia, Verrengia, Enrica, Lucchi, Sara, Oriani, Maria, Ginevra, Barchiesi, Michela, Pacetti, Monica, Magni, Laura, Rosa, Rossi, Giuseppe, Beneduce, Rossella, Tura, Giovanni, Battista, Laffranchini, Laura, Ferrato, Farida, Restaino, Francesco, Limosani, Ivan, Ghio, Lucio, Ferro, Maurizio, Parise, Vincenzo, Fricchione, Balletta, Giovanni, Addeo, Lelio, De Vivo, Elisa, Di Benedetto, Rossella, Pinna, Federica, Carpiniello, Bernardo, Spano, Mariangela, Giacomin, Marzio, Pecile, Damiano, Mattei, Chiara, Fabrici, Elisabetta, Pascolo, Panarello, Sofia, Peresson, Giulia, Vitucci, Claudio, Bonavigo, Tommaso, Perini, Giovanni, Boschello, Filippo, Strizzolo, Stefania, Gardellin, Francesco, Di Giannantonio, Massimo, Fizzotti, Carlo, Cossetta, Edoardo, Di Gregorio, Luana, Sozzi, Francesca, Boncompagni, Giancarlo, La Barbera, Daniele, Colli, Giuseppe, Laurenzi, Sabrina, Luca, Maria, D'Agostino A., Aguglia A., Barbui C., Bartoli F., Carra G., Cavallotti S., Chirico M., Ostinelli E.G., Zangani C., Martinotti G., Ostuzzi G., Nose M., Purgato M., Turrini G., Mazzi M.A., Papola D., Gastaldon C., Terlizzi S., Bertolini F., Piccoli A., Ruggeri M., De Fazio P., Magliocco F., Caroleo M., Raffaele G., Bergamelli E., Lucii C., Bolognesi S., Debolini S., Pierantozzi E., Fargnoli F., Del Zanna M., Giannini A., Luccarelli L., De Capua A., Annese P.M., Cerretini M., Tozzi F., Magnani N., Cardamone G., Bardicchia F., Facchi E., Soscia F., Zotos S., Biancosino B., Zonta F., Pompei F., Callegari C., Zizolfi D., Poloni N., Ielmini M., Caselli I., Giana E., Buzzi A., Diurni M., Milano A., Sani E., Calzolari R., Bortolaso P., Piccinelli M., Cazzamalli S., Alberini G., Piantanida S., Costantini C., Paronelli C., Di Caro A., Moretti V., Gozzi M., D'Ippolito C., Barbanti S.V., Alessandro P., Corbo M., Campese O., Fiori F., Lorusso M., Di Capro L., Viceconte D., Mancini V., Suraniti F., Signorelli M.S., Rossi E., Lupoli P., Menchetti M., Terzi L., Boso M., Risaro P., De Paoli G., Catania C., Tarricone I., Caretto V., Storbini V., Emiliani R., Balzarro B., Tabacchi T., Nava R., Bono A., Provenzi M., Brambilla G., Aspesi F., Trotta G., Tremolada M., Castagna G., Bava M., Verrengia E., Lucchi S., Oriani M.G., Barchiesi M., Pacetti M., Amerio A., Amore M., Serafini G., Magni L.R., Rossi G., Beneduce R., Tura G.B., Laffranchini L., Mastromo D., Ferrato F., Restaino F., Monzani E., Porcellana M., Limosani I., Ghio L., Ferro M., Parise V.F., Balletta G., Addeo L., De Vivo E., Di Benedetto R., Pinna F., Carpiniello B., Spano M., Giacomin M., Pecile D., Mattei C., Fabrici E.P., Panarello S., Peresson G., Vitucci C., Bonavigo T., Perini G., Boschello F., Strizzolo S., Gardellin F., di Giannantonio M., Moretti D., Fizzotti C., Cossetta E., Di Gregorio L., Sozzi F., Boncompagni G., La Barbera D., Colli G., Laurenzi S., Calandra C., Luca M., D'Agostino, A, Aguglia, A, Barbui, C, Bartoli, F, Carra, G, Cavallotti, S, Chirico, M, Ostinelli, E, Zangani, C, Martinotti, G, Ostuzzi, G, D'Agostino, Armando, Aguglia, Andrea, Barbui, Corrado, Bartoli, Francesco, Carrà, Giuseppe, Cavallotti, Simone, Chirico, Margherita, Ostinelli, Edoardo G, Zangani, Caroline, Martinotti, Giovanni, Ostuzzi, Giovanni, and LA BARBERA, DANIELE

Subjects
Long-acting injectable antipsychotic, Cross-Sectional Studies, Off-label, Personality disorder, Bipolar disorder, Delayed-Action Preparations, Schizophrenia, Humans, Long-acting injectable antipsychotics, Off-Label Use, Antipsychotic Agents, Settore MED/25 - Psichiatria
Abstract

Introduction: Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated with on– vs off–label LAIs and predictors of off–label First– or Second–Generation Antipsychotic (FGA vs. SGA) LAI choice in everyday clinical practice. Method: In a naturalistic national cohort of 449 patients who initiated LAI treatment in the STAR Network Depot Study, two groups were identified based on off– or on–label prescriptions. A multivariate logistic regression analysis was used to test several clinically relevant variables and identify those associated with the choice of FGA vs SGA prescription in the off–label group. Results: SGA LAIs were more commonly prescribed in everyday practice, without significant differences in their on– and off–label use. Approximately 1 in 4 patients received an off–label prescription. In the off–label group, the most frequent diagnoses were bipolar disorder (67.5%) or any personality disorder (23.7%). FGA vs SGA LAI choice was significantly associated with BPRS thought disorder (OR = 1.22, CI95% 1.04 to 1.43, p= 0.015) and hostility/suspiciousness (OR = 0.83, CI95% 0.71 to 0.97, p= 0.017) dimensions. The likelihood of receiving an SGA LAI grew steadily with the increase of the BPRS thought disturbance score. Conversely, a preference towards prescribing an FGA was observed with higher scores at the BPRS hostility/suspiciousness subscale. Conclusion: Our study is the first to identify predictors of FGA vs SGA choice in patients treated with off–label LAI antipsychotics. Demographic characteristics, i.e. age, sex, and substance/alcohol use co–morbidities did not appear to influence the choice towards FGAs or SGAs. Despite a lack of evidence, clinicians tend to favour FGA over SGA LAIs in bipolar or personality disorder patients with relevant hostility. Further research is needed to evaluate treatment adherence and clinical effectiveness of these prescriptive patterns.

Published
2022

27. Jumping to conclusions, general intelligence, and psychosis liability: Findings from the multi-centre EU-GEI case-control study

Author

Fabio Seminerio, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, Domenico Berardi, Jean-Paul Selten, Ilaria Tarricone, Peter B. Jones, Graham K. Murray, Miguel Bernardo, José Luis Santos, Pierre-Michel Llorca, Alexander Richards, Caterina La Cascia, Celso Arango, Manuel Arrojo, Victoria Rodriguez, Lieuwe de Haan, Craig Morgan, Crocettarachele Sartorio, Michael Conlon O'Donovan, Andrea Tortelli, Laura Ferraro, Julio Sanjuán, Robin M. Murray, Hannah E. Jongsma, Marta Di Forti, Cristina Marta Del-Ben, Eva Velthorst, Jim van Os, Daniele La Barbera, Bart P. F. Rutten, Julio Bobes, Sarah Tosato, Pak C. Sham, James B. Kirkbride, Paulo Rossi Menezes, Charlotte Gayer-Anderson, Giada Tripoli, Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Tripoli G., Quattrone D., Ferraro L., Gayer-Anderson C., Rodriguez V., La Cascia C., La Barbera D., Sartorio C., Seminerio F., Tarricone I., Berardi D., Szoke A., Arango C., Tortelli A., Llorca P.-M., De Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Jongsma H.E., Kirkbride J.B., Lasalvia A., Tosato S., Richards A., O'donovan M., Rutten B.P.F., Os J.V., Morgan C., Sham P.C., Murray R.M., Murray G.K., Di Forti M., Adult Psychiatry, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, Tripoli, Giada, Quattrone, Diego, Ferraro, Laura, Gayer-Anderson, Charlotte, Rodriguez, Victoria, La Cascia, Caterina, La Barbera, Daniele, Sartorio, Crocettarachele, Seminerio, Fabio, Tarricone, Ilaria, Berardi, Domenico, Szöke, Andrei, Arango, Celso, Tortelli, Andrea, Llorca, Pierre-Michel, de Haan, Lieuwe, Velthorst, Eva, Bobes, Julio, Bernardo, Miguel, Sanjuán, Julio, Santos, Jose Lui, Arrojo, Manuel, Del-Ben, Cristina Marta, Menezes, Paulo Rossi, Selten, Jean-Paul, Jones, Peter B, Jongsma, Hannah E, Kirkbride, James B, Lasalvia, Antonio, Tosato, Sarah, Richards, Alex, O'Donovan, Michael, Rutten, Bart Pf, Os, Jim van, Morgan, Craig, Sham, Pak C, Murray, Robin M, Murray, Graham K, Di Forti, Marta, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: MA Psychiatrie (3), and MUMC+: Hersen en Zenuw Centrum (3)

Subjects
Male, MISCOMPREHENSION, Intelligence, DELÍRIO, 0302 clinical medicine, Cognition, SCHIZOPHRENIA, psychotic-like experience, jumping to conclusions, Applied Psychology, Problem Solving, RISK, education.field_of_study, Middle Aged, 16. Peace & justice, Cognitive bias, 3. Good health, First episode psychosis, IQ, polygenic risk score, psychotic-like experiences, symptom dimensions, Psychiatry and Mental health, BIAS, Schizophrenia, RELIABILITY, Female, Original Article, jumping to conclusion, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], medicine.symptom, Clinical psychology, Adult, Psychosis, Adolescent, DISORDERS, Population, REEXAMINATION, Delusions, 03 medical and health sciences, Young Adult, PEOPLE, medicine, Humans, Cognitive Dysfunction, education, DELUSIONAL IDEATION, Cognitive deficit, business.industry, Case-control study, medicine.disease, First episode psychosi, 030227 psychiatry, Psychotic Disorders, Case-Control Studies, Jumping to conclusions, business, 030217 neurology & neurosurgery
Abstract

This study was funded by the Medical Research Council, the European Community’s Seventh Framework Program grant [agreement HEALTH-F2-2009-241909 (Project EU-GEI)], São Paulo Research Foundation (grant 2012/0417-0), the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London, the NIHR BRC at University College London and the Wellcome Trust (grant 101272/Z/12/Z)., Tripoli, G., Quattrone, D., Ferraro, L., Gayer-Anderson, C., Rodriguez, V., La Cascia, C., La Barbera, D., Sartorio, C., Seminerio, F., Tarricone, I., Berardi, D., Szöke, A., Arango, C., Tortelli, A., Llorca, P.-M., De Haan, L., Velthorst, E., Bobes, J., Bernardo, M., Sanjuán, J., Santos, J.L., Arrojo, M., Del-Ben, C.M., Menezes, P.R., Selten, J.-P., Jones, P.B., Jongsma, H.E., Kirkbride, J.B., Lasalvia, A., Tosato, S., Richards, A., O'donovan, M., Rutten, B.P.F., Os, J.V., Morgan, C., Sham, P.C., Murray, R.M., Murray, G.K., Di Forti, M.

Published
2021

28. Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study

Author

Francesco Bartoli, A, Daniele Cavaleri, A, Tommaso Callovini, A, Ilaria Riboldi, A, Cristina Crocamo, A, Armando D’Agostino, B, Giovanni Martinotti, C, Federico Bertolini, D, Giovanni Ostuzzi, D, Corrado Barbui, D, Giuseppe Carr`a, A, STAR Network Depot Investigators, Corrado, Barbui, Federico, Bertolini, Filippo, Boschello, Chiara, Gastaldon, Maria Angela Mazzi, Michela, Nos´e, Giovanni, Ostuzzi, Davide, Papola, Giovanni, Perini, Alberto, Piccoli, Michela, Pievani, Marianna, Purgato, Mirella, Ruggeri, Federico, Tedeschi, Samira, Terlizzi, and Giulia Turrini (Verona), Mariarita, Caroleo, Pasquale De Fazio, Fabio, Magliocco, and Gaetano Raffaele (Catanzaro), Simone, Cavallotti, Margherita, Chirico, Armando, D’Agostino, Farida, Ferrato, Ivan, Limosani, Daniele, Mastromo, Emiliano, Monzani, Edoardo Giuseppe Ostinelli, Matteo, Porcellana, and Francesco Restaino (Milano), Pasqua Maria Annese, Simone, Bolognesi, Massimiliano, Cerretini, Alberto De Capua, Sara, Debolini, Maria Del Zanna, Francesco, Fargnoli, Alessandra, Giannini, Livia, Luccarelli, Claudio, Lucii, Elisa, Pierantozzi, and Fiorella Tozzi (Siena), Francesco, Bardicchia, Giuseppe, Cardamone, Edvige, Facchi, Nadia, Magnani, and Federica Soscia (Grosseto), Bruno Biancosino, and Spyridon Zotos (Ferrara), Marzio, Giacomin, Francesco, Pompei, Mariangela, Spano, and Filippo Zonta (Treviso), Buzzi, ALDO EMANUELE, Callegari, Camilla, Roberta, Calzolari, Caselli, Ivano, Marcello, Diurni, Edoardo Luigi Giana, Ielmini, Marta, Anna, Milano, Emanuele, Sani, and Daniele Zizolfi (Varese), Gabrio, Alberini, Paola, Bortolaso, Sara, Cazzamalli, Chiara, Costantini, Angela Di Caro, Chiara, Paronelli, Silvia, Piantanida, and Marco Piccinelli (Varese Verbano), Papalini, Alessandro, Silva Veronica Barbanti, Chiara, D’Ippolito, Mauro, Gozzi, and Valentina Moretti (Reggio Emilia), Ornella, Campese, Mariangela, Corbo, Lucia Di Capro, Massimo di Giannantonio, Federica, Fiori, Marco, Lorusso, Valerio, Mancini, Giovanni, Martinotti, and Daniela Viceconte (Chieti), Carmela, Calandra, Maria, Luca, Maria Salvina Signorelli, and Francesco Suraniti (Catania), Beatrice, Balzarro, Giancarlo, Boncompagni, Valentina, Caretto, Roberta, Emiliani, Pasqualino, Lupoli, Marco, Menchetti, Eugenio, Rossi, Viviana, Storbini, Ilaria, Tarricone, and Laura Terzi (Bologna), Marianna, Boso, Cristina, Catania, Giuseppe De Paoli, and Paolo Risaro (Pavia), Flora, Aspesi, Francesco, Bartoli, Mattia, Bava, Adele, Bono, Giulia, Brambilla, Giuseppe, Carr`a, Gloria, Castagna, Sara, Lucchi, Roberto, Nava, Milena, Provenzi, Tommaso, Tabacchi, Martina, Tremolada, and Enrica Verrengia (Monza), Michela Barchiesi and Maria Ginevra Oriani (Ancona), Monica Pacetti (Forlì), Andrea, Aguglia, Maurizio, Ferro, and Lucio Ghio (Genova), Rossella, Beneduce, Laura, Laffranchini, Laura Rosa Magni, Giuseppe, Rossi, and Giovanni Battista Tura (Brescia), Lelio, Addeo, Giovanni, Balletta, Elisa De Vivo, Rossella Di Benedetto, and Vincenzo Fricchione Parise (Avellino), Bernardo Carpiniello and Federica Pinna (Cagliari), Damiano Pecile (Mantova), Chiara Mattei (Fermo), Tommaso, Bonavigo, Elisabetta Pascolo Fabrici, Sofia, Panarello, Giulia, Peresson, and Claudio Vitucci (Trieste), Francesco Gardellin, and Stefania Strizzolo (Vicenza), Edoardo, Cossetta, Carlo, Fizzotti, and Daniele Moretti (Savona), Luana Di Gregorio and Francesca Sozzi (Trento), Giuseppe Colli and Daniele La Barbera (Palermo), and Sabrina Laurenzi (Civitanova, Marche)., Bartoli, F, Cavaleri, D, Callovini, T, Riboldi, I, Crocamo, C, D'Agostino, A, Martinotti, G, Bertolini, F, Ostuzzi, G, Barbui, C, Carra, G, and Bartoli, F., Cavaleri, D., Callovini, T., Riboldi, I., Crocamo, C., D'Agostino, A., Martinotti, G., Bertolini, F., Ostuzzi, G., Barbui, C., Carrà, G., Boschello, F., Gastaldon, C., Mazzi, M.A., Nosé, M., Papola, D., Perini, G., Piccoli, A., Pievani, M., Purgato, M., Ruggeri, M., Tedeschi, F., Terlizzi, S., Turrini, G., Caroleo, M., De Fazio, P., Magliocco, F., Raffaele, G., Chirico, M., Ferrato, F., Limosani, I., Mastromo, D., Monzani, E., Ostinelli, E.G., Porcellana, M., Restaino, F., Annese, P.M., Bolognesi, S., Cerretini, M., De Capua, A., Debolini, S., Del Zanna, M., Fargnoli, F., Giannini, A., Luccarelli, L., Lucii, C., Pierantozzi, E., Tozzi, F., Bardicchia, F., Cardamone, G., Facchi, E., Magnani, N., Soscia, F., Biancosino, B., Zotos, S., Giacomin, M., Pompei, F., Spano, M., Zonta, F., Buzzi, A., Callegari, C., Calzolari, R., Caselli, I., Diurni, M., Giana, E.L., Ielmini, M., Milano, A., Poloni, N., Sani, E., Zizolfi, D., Alberini, G., Bortolaso, P., Cazzamalli, S., Costantini, C., Di Caro, A., Paronelli, C., Piantanida, S., Piccinelli, M., Alessandro, P., Barbanti, S.V., D'Ippolito, C., Gozzi, M., Moretti, V., Corbo, M., Di Capro, L., di Giannantonio, M., Fiori, F., Lorusso, M., Mancini, V., Viceconte, D., Calandra, C., Luca, M., Signorelli, M.S., Suraniti, F., Balzarro, B., Boncompagni, G., Caretto, V., Emiliani, R., Lupoli, P., Menchetti, M., Rossi, E., Storbini, V., Tarricone, I., Terzi, L., Boso, M., Catania, C., De Paoli, G., Risaro, P., Aspesi, F., Bava, M., Bono, A., Brambilla, G., Castagna, G., Lucchi, S., Nava, R., Provenzi, M., Tabacchi, T., Tremolada, M., Verrengia, E., Barchiesi, M., Oriani, M.G., Aguglia, A., Ferro, M., Ghio, L., Beneduce, R., Laffranchini, L., Magni, L.R., Rossi, G., Tura, G.B., Addeo, L., Balletta, G., De Vivo, E., Di Benedetto, R., Parise, V.F., Carpiniello, B., Pinna, F., Pecile, D., Mattei, C., Bonavigo, T., Fabrici, E.P., Panarello, S., Peresson, G., Vitucci, C., Pacetti, M., Gardellin, F., Strizzolo, S., Cossetta, E., Fizzotti, C., Moretti, D., Di Gregorio, L., Sozzi, F., Colli, G., La Barbera, D., Laurenzi, S.

Subjects
Long-acting injectable antipsychotic, Paliperidone palmitate 1-month, Aripiprazole, Aripiprazole monohydrate, Long-acting injectable antipsychotics, Psychiatry and Mental health, Paliperidone Palmitate, Schizophrenia, Humans, Prospective Studies, Settore MED/25 - Psichiatria, Biological Psychiatry, Antipsychotic Agents
Abstract

In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.

Published
2022

29. Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis

Author

Robin M. Murray, Luis Alameda, Andrea Tortelli, Laura Ferraro, Cristina Marta Del-Ben, Eva Velthorst, Peter B. Jones, Monica Aas, James B. Kirkbride, Pierre-Michel Llorca, Evangelos Vassos, Hannah E. Jongsma, Paola Dazzan, Jean-Paul Selten, Miguel Bernardo, Victoria Rodriguez, Lieuwe de Haan, Marta Di Forti, Jose Luis Santos, Roberto Muratori, Caterina La Cascia, Manuel Arrojo, Pak C. Sham, Jim van Os, Bart P. F. Rutten, Daniele La Barbera, Celso Arango, Ilaria Tarricone, Domenico Berardi, Sarah Tosato, Craig Morgan, Julio Bobes, Paulo Rossi Menezes, Antonella Trotta, Julio Sanjuán, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, Charlotte Gayer-Anderson, Giada Tripoli, Aas M., Alameda L., Di Forti M., Quattrone D., Dazzan P., Trotta A., Ferraro L., Rodriguez V., Vassos E., Sham P., Tripoli G., La Cascia C., La Barbera D., Tarricone I., Muratori R., Berardi D., Lasalvia A., Tosato S., Szoke A., Llorca P.-M., Arango C., Tortelli A., De Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Jongsma H.E., Kirkbride J.B., Rutten B.P.F., Van Os J., Gayer-Anderson C., Murray R.M., Morgan C., Cascia C.L., Barbera D.L., RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R2 - Mental Health, MUMC+: Hersen en Zenuw Centrum (3), Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
SCHIZOPHRENIA SPECTRUM, medicine.medical_specialty, GENES, polygenic risk, first-episode psychosi, ILLNESS, interaction contrast ratio, Childhood trauma, DOPAMINE, First episode psychosis, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, MALTREATMENT, Medicine, first-episode psychosis, ABUSE, Psychiatry, Settore MED/25 - Psichiatria, Applied Psychology, TRAUMA, ENVIRONMENT, business.industry, medicine.disease, schizophrenia, Psychiatry and Mental health, Schizophrenia, RELIABILITY, Polygenic risk score, synergistic effects, business
Abstract

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme., Aas, M; Alameda, L; Di Forti, M; Quattrone, D; Dazzan, P; Trotta, A; Ferraro, L; Rodriguez, V; Vassos, E; Sham, P; Tripoli, G; La Cascia, C; La Barbera, D; Tarricone, I; Muratori, R; Berardi, D; Lasalvia, A; Tosato, S; Szoke, A; Llorca, PM; Arango, C; Tortelli, A; de Haan, L; Velthorst, E; Bobes, J; Bernardo, M; Sanjuan, J; Santos, JL; Arrojo, M; Del-Ben, CM; Menezes, PR; Selten, JP; Jones, PB; Jongsma, HE; Kirkbride, JB; Rutten, BPF; van Os, J; Gayer-Anderson, C; Murray, RM; Morgan, C

Published
2021

30. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

Author

Quattrone, Diego, Reininghaus, Ulrich, Richards, Alex L., Tripoli, Giada, Ferraro, Laura, Quattrone, Andrea, Marino, Paolo, Rodriguez, Victoria, Spinazzola, Edoardo, Gayer-Anderson, Charlotte, Jongsma, Hannah E., Jones, Peter B., La Cascia, Caterina, La Barbera, Daniele, Tarricone, Ilaria, Bonora, Elena, Tosato, Sarah, Lasalvia, Antonio, Szöke, Andrei, Arango, Celso, Bernardo, Miquel, Bobes, Julio, Del Ben, Cristina Marta, Menezes, Paulo Rossi, Llorca, Pierre-Michel, Santos, Jose Luis, Sanjuán, Julio, Arrojo, Manuel, Tortelli, Andrea, Velthorst, Eva, Berendsen, Steven, de Haan, Lieuwe, Rutten, Bart P. F., Lynskey, Michael T., Freeman, Tom P., Kirkbride, James B., Sham, Pak C., O'Donovan, Michael C., Cardno, Alastair G., Vassos, Evangelos, van Os, Jim, Morgan, Craig, Murray, Robin M., Lewis, Cathryn M., Di Forti, Marta, Hubbard, Kathryn, Beards, Stephanie, Stilo, Simona A., Parellada, Mara, Fraguas, David, Castro, Marta Rapado, Andreu-Bernabeu, Álvaro, López, Gonzalo, Matteis, Mario, González, Emiliano, Durán-Cutilla, Manuel, Díaz-Caneja, Covadonga M., Cuadrado, Pedro, Rodríguez Solano, José Juan, Carracedo, Angel, Costas, Javier, Sánchez, Emilio, Amoretti, Silvia, Lorente-Rovira, Esther, Garcia-Portilla, Paz, Jiménez-López, Estela, Franke, Nathalie, van Dam, Daniella, Termorshuizen, Fabian, van der Ven, Elsje, Messchaart, Elles, Leboyer, Marion, Schu?rhoff, Franck, Jamain, Stéphane, Baudin, Grégoire, Ferchiou, Aziz, Pignon, Baptiste, Richard, Jean-Romain, Charpeaud, Thomas, Tronche, Anne-Marie, Frijda, Flora, Marrazzo, Giovanna, Sideli, Lucia, Sartorio, Crocettarachele, Seminerio, Fabio, Loureiro, Camila Marcelino, Shuhama, Rosana, Ruggeri, Mirella, Bonetto, Chiara, Cristofalo, Doriana, Berardi, Domenico, Seri, Marco, D?Andrea, Giuseppe, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, RS: MHeNs - R3 - Neuroscience, MUMC+: MA Psychiatrie (3), MUMC+: Hersen en Zenuw Centrum (3), Quattrone D., Reininghaus U., Richards A.L., Tripoli G., Ferraro L., Quattrone A., Marino P., Rodriguez V., Spinazzola E., Gayer-Anderson C., Jongsma H.E., Jones P.B., La Cascia C., La Barbera D., Tarricone I., Bonora E., Tosato S., Lasalvia A., Szoke A., Arango C., Bernardo M., Bobes J., Del Ben C.M., Menezes P.R., Llorca P.-M., Santos J.L., Sanjuan J., Arrojo M., Tortelli A., Velthorst E., Berendsen S., de Haan L., Rutten B.P.F., Lynskey M.T., Freeman T.P., Kirkbride J.B., Sham P.C., O'Donovan M.C., Cardno A.G., Vassos E., van Os J., Morgan C., Murray R.M., Lewis C.M., Di Forti M., Hubbard K., Beards S., Stilo S.A., Parellada M., Fraguas D., Castro M.R., Andreu-Bernabeu A., Lopez G., Matteis M., Gonzalez E., Duran-Cutilla M., Diaz-Caneja C.M., Cuadrado P., Rodriguez Solano J.J., Carracedo A., Costas J., Sanchez E., Amoretti S., Lorente-Rovira E., Garcia-Portilla P., Jimenez-Lopez E., Franke N., van Dam D., Termorshuizen F., van der Ven E., Messchaart E., Leboyer M., Schurhoff F., Jamain S., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., Frijda F., Marrazzo G., Sideli L., Sartorio C., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Bonetto C., Cristofalo D., Berardi D., Seri M., D'Andrea G., Quattrone, Diego [0000-0002-6051-8309], Richards, Alex L [0000-0003-3218-7247], Marino, Paolo [0000-0003-3571-1753], Rodriguez, Victoria [0000-0003-0383-0846], Jones, Peter B [0000-0002-0387-880X], Tosato, Sarah [0000-0002-9665-7538], Bernardo, Miquel [0000-0001-8748-6717], Bobes, Julio [0000-0003-2187-4033], Del Ben, Cristina Marta [0000-0003-0145-9975], Menezes, Paulo Rossi [0000-0001-6330-3314], Llorca, Pierre-Michel [0000-0001-7438-8990], Rutten, Bart PF [0000-0002-9834-6346], Kirkbride, James B [0000-0003-3401-0824], O'Donovan, Michael C [0000-0001-7073-2379], Vassos, Evangelos [0000-0001-6363-0438], Murray, Robin M [0000-0003-0829-0519], Lewis, Cathryn M [0000-0002-8249-8476], Apollo - University of Cambridge Repository, Rutten, Bart P F [0000-0002-9834-6346], Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
medicine.medical_specialty, Psychosis, Population, Neurosciences. Biological psychiatry. Neuropsychiatry, PHENOTYPES, ILLNESS, Psychotic Disorder, Predictive markers, Article, Cellular and Molecular Neuroscience, DEFICIT SYNDROME, Risk Factors, First episode psychosis, medicine, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Humans, Cannabi, Clinical genetics, Genetic risk, VALIDITY, education, Settore MED/25 - Psichiatria, SCHEDULE, Biological Psychiatry, METAANALYSIS, Cannabis, UTILITY, education.field_of_study, Risk Factor, ESQUIZOFRENIA, ASSOCIATION, Cannabis use, medicine.disease, BIFACTOR MODEL, Psychiatry and Mental health, Psychotic Disorders, INTERRATER RELIABILITY, Schizophrenia, Linear Models, Linear Model, Medical genetics, Polygenic risk score, Psychology, Human, RC321-571, Clinical psychology
Abstract

The work was supported by Guarantors of Brain post-doctoral clinical fellowship to DQ; Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; Heisenberg professorship from the German Research Founda- tion (grant no. 389624707) to UR; the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0., Quattrone D., Reininghaus U., Richards A.L., Tripoli G., Ferraro L., Quattrone A., Marino P., Rodriguez V., Spinazzola E., Gayer-Anderson C., Jongsma H.E., Jones P.B., La Cascia C., La Barbera D., Tarricone I., Bonora E., Tosato S., Lasalvia A., Szöke A., Arango C., Bernardo M., Bobes J., Del Ben C.M., Menezes P.R., Llorca P.-M., Santos J.L., Sanjuán J., Arrojo M., Tortelli A., Velthorst E., Berendsen S., de Haan L., Rutten B.P.F., Lynskey M.T., Freeman T.P., Kirkbride J.B., Sham P.C., O’Donovan M.C., Cardno A.G., Vassos E., van Os J., Morgan C., Murray R.M., Lewis C.M., Di Forti M., Hubbard K., Beards S., Stilo S.A., Parellada M., Fraguas D., Castro M.R., Andreu-Bernabeu Á., López G., Matteis M., González E., Durán-Cutilla M., Díaz-Caneja C.M., Cuadrado P., Rodríguez Solano J.J., Carracedo A., Costas J., Sánchez E., Amoretti S., Lorente-Rovira E., Garcia-Portilla P., Jiménez-López E., Franke N., van Dam D., Termorshuizen F., van der Ven E., Messchaart E., Leboyer M., Schürhoff F., Jamain S., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., Frijda F., Marrazzo G., Sideli L., Sartorio C., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Bonetto C., Cristofalo D., Berardi D., Seri M., D’Andrea G.

Published
2021

31. The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study

Author

Giada Tripoli, Evangelos Vassos, Jennifer O'Connor, Oleysa Ajnakina, Robin M. Murray, Paola Dazzan, Tabea Schoeler, M A Falcone, G Trotta, Antonella Trotta, Sagnik Bhattacharyya, C. La Cascia, Victoria Rodriguez, Valeria Mondelli, Luis Alameda, Craig Morgan, Marco Colizzi, Tiago Reis Marques, Conrad Iyegbe, Javier-David Lopez-Morinigo, Anthony S. David, D. La Barbera, Lucia Sideli, Laura Ferraro, Simona A. Stilo, Fiona Gaughran, M. Di Forti, Diego Quattrone, Murray R.M., Mondelli V., Stilo S.A., Trotta A., Sideli L., Ajnakina O., Ferraro L., Vassos E., Iyegbe C., Schoeler T., Bhattacharyya S., Marques T.R., Dazzan P., Lopez-Morinigo J., Colizzi M., O'Connor J., Falcone M.A., Quattrone D., Rodriguez V., Tripoli G., La Barbera D., La Cascia C., Alameda L., Trotta G., Morgan C., Gaughran F., David A., and Di Forti M.

Subjects
Psychosis, Hypothalamo-Hypophyseal System, Vulnerability, Multidisciplinary study, Ethnic group, Pituitary-Adrenal System, Psychosi, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, London, medicine, Ethnicity, Humans, First episode, Child, Biological Psychiatry, Minority Groups, Outcome, Markers, Schizophrenia, biology, business.industry, Marker, medicine.disease, biology.organism_classification, 030227 psychiatry, Psychotic Disorders, Psychiatry and Mental health, Increased risk, Jumping to conclusions, Cannabis, business, 030217 neurology & neurosurgery, Clinical psychology
Abstract

The GAP multidisciplinary study carried out in South London, recruited 410 first episode of psychosis patients and 370 controls; the aim was to elucidate the multiple genetic and environmental factors influencing the onset and outcome of psychosis. The study demonstrated the risk increasing effect of adversity in childhood (especially parental loss, abuse, and bullying) on onset of psychosis especially positive symptoms. Adverse life events more proximal to onset, being from an ethnic minority, and cannabis use also played important roles; indeed, one quarter of new cases of psychosis could be attributed to use of high potency cannabis. The “jumping to conclusions” bias appeared to mediate the effect of lower IQ on vulnerability to psychosis. We confirmed that environmental factors operate on the background of polygenic risk, and that genetic and environment act together to push individuals over the threshold for manifesting the clinical disorder. The study demonstrated how biological pathways involved in the stress response (HPA axis and immune system) provide important mechanisms linking social risk factors to the development of psychotic symptoms. Further evidence implicating an immune/inflammatory component to psychosis came from our finding of complement dysregulation in FEP. Patients also showed an upregulation of the antimicrobial alpha-defensins, as well as differences in expression patterns of genes involved in NF-κB signaling and Cytokine Production. Being of African origin not only increased risk of onset but also of a more difficult course of illness. The malign effect of childhood adversity predicted a poorer outcome as did continued use of high potency cannabis.

Published
2020

32. Evaluating the feasibility of the Italian version of the computerized interactive remediation of cognition training for schizophrenia (circuits)

Author

Fabio Seminerio, Crocettarachele Sartorio, Daniele La Barbera, Giuseppe Colli, G Tripoli, Filippo La Paglia, Lucia Sideli, Caterina La Cascia, Matteo Cella, Alessandra Scaglione, Domenica Matranga, Giuseppe Maniaci, Rosa Lo Baido, Laura Ferraro, la Cascia C., Ferraro L., Seminerio F., Scaglione A., Maniaci G., Matranga D., Sideli L., Colli G., Sartorio C., La Paglia F., Tripoli G., Lo Baido R., Cella M., and La Barbera D.

Subjects
Rehabilitation, Schizophrenia (object-oriented programming), medicine.medical_treatment, Metacognition, Cognition, Psychiatry and Mental health, Computer, Pilot project, Settore M-PSI/08 - Psicologia Clinica, medicine, Schizophrenia, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Psychology, Settore MED/25 - Psichiatria, Cognitive psychology
Abstract

Background: Circuits is a computerized cognitive remediation program for individuals with schizophrenia. this study aimed to evaluate the feasibility of the italian version of circuits. MethODs: Feasibility was measured through ad-hoc questionnaires in a non-clinical sample (N.=30; target-score 70%; study 1); in patients with schizophrenia (N.=5; target-score 60%; study 2) and cr therapists (N.=3; target-score 60%; study 2). study 3 was a pilot study investigating: 1) enrolment, compliance, and retention rates; 2) satisfaction; 3) potential post-treatment and follow-up improvements in patients with schizophrenia (N.=20). these results were used to estimate sample size and feasibility for a future trial. resULts: all non-clinical participants rated high feasibility of circuits (83.3-100% scores). all patients (60-100% high-scores) and cr therapists (66-100% high-scores) evaluated circuits feasible. high rates of retention in treatment (74.5%) and satisfaction (85-100%) in patients were showed. Post-treatment assessment revealed an improvement in all cognitive measures. a sample size of 32 was calculated for each arm of the trial, at the desired power of 80%, to recruit for 18 months. cONcLUsiONs: results showed the feasibility of the italian version of circuits, they will inform a controlled future trial and implementation study of this therapy approach in the italian mental health system.

Published
2020

33. Low incidence of psychosis in Italy: confirmation from the first epidemiological study in Sicily

Author

Alice Mulè, Robin M. Murray, F. Seminerio, Paul Fearon, Veronica Capuccio, C. La Cascia, D. La Barbera, M. Di Forti, Crocettarachele Sartorio, Laura Ferraro, Lucia Sideli, James B. Kirkbride, Giada Tripoli, Mulè, A., Sideli, L., Capuccio, V., Fearon, P., Ferraro, L., Kirkbride, J., LA CASCIA, C., Sartorio, C., Seminerio, F., Tripoli, G., Di Forti, M., LA BARBERA, D., and Murray, R.

Subjects
Adult, Male, medicine.medical_specialty, Health (social science), Adolescent, Social Psychology, Epidemiology, Psychosi, Rate ratio, Article, Young Adult, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, medicine, Humans, Poisson regression, Psychiatry, Settore MED/25 - Psichiatria, Sicily, Aged, First episode, business.industry, Incidence, Incidence (epidemiology), Middle Aged, Psychosis, medicine.disease, Confidence interval, 030227 psychiatry, Epidemiologic Studies, Psychiatry and Mental health, Italy, Psychotic Disorders, Schizophrenia, Etiology, symbols, population characteristics, Female, business, Settore M-PSI/05 - Psicologia Sociale, 030217 neurology & neurosurgery, Demography
Abstract

Purpose: The incidence of psychotic disorders varies in different geographical areas. As there have been no reports from Southern Italy, this study aimed to determine the incidence rate of first-episode psychosis in Palermo, Sicily. Methods: All patients, aged 18–65 years, presenting with a first episode of psychosis (FEP) (ICD-10 F20–29, F30–33) to mental health services in Palermo, were recorded over a 3-year period. Incidence rates of psychotic disorders and their 95% confidence intervals (95% CI) were estimated. Poisson regression was applied to estimate the differences in incidence rate ratio (IRR) by age, sex and migrant status. Results: Two hundred and four FEP participants were identified during the 3 years; 183 (89.7%, males n = 112) participants were native Italians and 21 were migrants (10.3%, males n = 14). The crude incidence of all psychoses was 15.9 (95% CI 13.7–18.1). As predicted, the risk of schizophrenia F20 was higher in males compared to females (adjusted IRR = 1.99, 95% CI 1.36–2.88) and in migrants compared to native Italians (adjusted IRR = 4.02, 95% CI 2.39–6.75). Conclusions: This study, the first from Sicily, confirms previous findings from Northern Italy that the risk of schizophrenia and other psychoses is much lower in Italian cities than those reported from cities in Northern Europe; the reasons for this disparity may provide important clues to the aetiology of psychosis.

Published
2016

34. Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study

Author

Misra, Supriya, Gelaye, Bizu, Koenen, Karestan C, Williams, David R, Borba, Christina PC, Quattrone, Diego, Di Forti, Marta, La Cascia, Caterina, La Barbera, Daniele, Tarricone, Ilaria, Berardi, Domenico, Szöke, Andrei, Arango, Celso, Tortelli, Andrea, De Haan, Lieuwe, Velthorst, Eva, Bobes, Julio, Bernardo, Miguel, Sanjuán, Julio, Santos, Jose Luis, Arrojo, Manuel, Del-Ben, Cristina Marta, Menezes, Paulo Rossi, Selten, Jean-Paul, Jones, Peter B, Kirkbride, James B, EU-GEI WP2 Group, Rutten, Bart PF, Van Os, Jim, Murray, Robin M, Gayer-Anderson, Charlotte, Morgan, Craig, Misra S., Gelaye B., Koenen K.C., Williams D.R., Borba C.P.C., Quattrone D., Di Forti M., La Cascia C., La Barbera D., Tarricone I., Berardi D., Szoke A., Arango C., Tortelli A., de Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Kirkbride J.B., Rutten B.P.F., Os J., Murray R.M., Gayer-Anderson C., Morgan C., Supriya Misra, Bizu Gelaye, Karestan C. Koenen, David R. Williams, Christina P.C. Borba, Diego Quattrone, Marta Di Forti, Caterina La Cascia, Daniele La Barbera, Ilaria Tarricone, Domenico Berardi, Andrei Szöke, Celso Arango, Andrea Tortelli, Lieuwe de Haan, Eva Velthorst, Julio Bobes, Miguel Bernardo, Julio Sanjuán, Jose Luis Santos, Manuel Arrojo, Cristina Marta Del-Ben, Paulo Rossi Menezes, Jean-Paul Selten, Peter B. Jones, James B. Kirkbride, EU-GEI WP2 Group, Bart P.F. Rutten, Jim van Os, Robin M. Murray, Charlotte Gayer-Anderson, Craig Morgan, Misra, Supriya [0000-0003-0389-1227], Quattrone, Diego [0000-0002-6051-8309], Bobes, Julio [0000-0003-2187-4033], Bernardo, Miguel [0000-0001-8748-6717], Menezes, Paulo Rossi [0000-0001-6330-3314], Kirkbride, James B [0000-0003-3401-0824], Murray, Robin M [0000-0003-0829-0519], Apollo - University of Cambridge Repository, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R3 - Neuroscience, RS: MHeNs - R2 - Mental Health, MUMC+: Hersen en Zenuw Centrum (3), APH - Mental Health, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, and Adult Psychiatry

Subjects
ESTUDO DE CASO, STRESS, CHILDHOOD, lcsh:Medicine, childhood adversities, psychosi, Parental Death, 0302 clinical medicine, Psicosi en els infants, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Medicine, early parental death, psychosis, Dol, RACE, General Medicine, Infants Salut mental, childhood adversitie, Esquizofrènia, Maternal death, HEALTH, case-control, early bereavement, DISORDERS, Offspring, DISADVANTAGE, ethnic minorities, ethnic minoritie, Article, Odds, 03 medical and health sciences, BEREAVEMENT, Journal Article, Mortalitat, Psiquiatria, Mortality, Risk factor, Settore MED/25 - Psichiatria, METAANALYSIS, multi-country, business.industry, MORTALITY, lcsh:R, Case-control study, Odds ratio, medicine.disease, Confidence interval, 030227 psychiatry, population-based, schizophrenia, Psychoses in children, business, 030217 neurology & neurosurgery, Bereavement, Demography
Abstract

Evidence for early parental death as a risk factor for psychosis in offspring is inconclusive. We analyzed data from a six-country, case-control study to examine the associations of early parental death, type of death (maternal, paternal, both), and child’s age at death with psychosis, both overall and by ethnic group. In fully adjusted multivariable mixed-effects logistic regression models, experiencing early parental death was associated with 1.54-fold greater odds of psychosis (95% confidence interval (CI): 1.23, 1.92). Experiencing maternal death had 2.27-fold greater odds (95% CI: 1.18, 4.37), paternal death had 1.14-fold greater odds (95% CI: 0.79, 1.64), and both deaths had 4.42-fold greater odds (95% CI: 2.57, 7.60) of psychosis compared with no early parental death. Experiencing parental death between 11 and 16 years of age had 2.03-fold greater odds of psychosis than experiencing it before five years of age (95% CI: 1.02, 4.04). In stratified analyses, experiencing the death of both parents had 9.22-fold greater odds of psychosis among minority ethnic groups (95% CI: 2.02−28.02) and no elevated odds among the ethnic majority (odds ratio (OR): 0.96; 95% CI: 0.10−8.97), which could be due in part to the higher prevalence of early parental death among minority ethnic groups but should be interpreted cautiously given the wide confidence intervals.

Published
2019
Full Text
View/download PDF

35. Bridging the gap between research into biological and psychosocial models of psychosis

Author

Murray, RM, SIDELI, Lucia, LA CASCIA, Caterina, LA BARBERA, Daniele, Murray, RM, Sideli, L, La Cascia, C, and La Barbera, D.

Subjects
schizophrenia, neurodevelopment, Settore M-PSI/08 - Psicologia Clinica, Commentary, dopamine, genetics, psychosis, social factors, genetic, psychosi, Settore MED/25 - Psichiatria
Abstract

Paul Bebbington's recent Special Article provides an excellent synthesis of recent advances in psychosocial research on psychosis. However, we doubt that a model based solely on social epidemiology and cognitive theory can totally describe psychosis, and to be fair, Bebbington does not suggest that it does. A complete model must also incorporate what we have learned from non-social epidemiology, neuroscience, and genetics. Evidence indicates that both the social risk factors that interest Bebbington and biological risk factors, such as abuse of stimulants and cannabis, can provoke psychotic symptoms by dysregulating striatal dopamine. The role of neurodevelopmental deviance also needs to be considered in the etiology of schizophrenia-like psychosis. Moreover, the striking advances in our understanding of the genetic architecture of psychosis open an exciting door into studies examining gene-environment correlation and gene-environment interaction. In short, Bebbington demonstrates the value of cognitive and social researchers talking to each other, but the occasional chat with the more biologically inclined could produce a more comprehensive model.Paul Bebbington 最近发表的专题文章对精神病的社会心理学研究的最新进展做了一个极好的综述。然而，我们对一个仅仅基于社会流行病学和认知理论的模型可以完全描述精神病持有疑虑，并且公平地说，Bebbington 也不认为这个模型可以完全描述。一个完整的模型必须纳入我们从非社会流行病学、神经科学和遗传学中汲取的经验教训。有证据表明，Bebbington 感兴趣的社会风险因素，和诸如滥用兴奋剂和大麻之类的生物危险因素都可以通过纹状体多巴胺失调而激发精神病症状。在精神分裂症样精神病的病因学中，我们也需要考虑神经发育异常。此外，我们对精神病的遗传学理解上的惊人进展为研究探讨基因- 环境相关性和基因-环境相互作用打开一扇令人兴奋的大门。总之，Bebbington 阐述了认知领域的学者与社会研究者互相交流的价值，但偶尔更倾向于生物学方面的角度可能发展出一个更全面的模型。.本文全文中文版从2015年8月6日起在http://dx.doi.org/10.11919/j.issn.1002-0829.215067可供免费阅览下载.

Published
2015

36. Development of a new measure for assessing insight: Psychometric properties of the insight orientation scale (IOS)

Author

Franca Tani, Alessio Gori, Gian Mauro Manzoni, Daniel Dewey, Marco Giannini, Gianluca Castelnuovo, Lucia Ponti, David Schuldberg, Yura Loscalzo, Daniele La Barbera, Vincenzo Caretti, Giuseppe Craparo, Gori, A., Craparo, G., Giannini, M., Loscalzo, Y., Caretti, V., LA BARBERA, D., Manzoni, G., Castelnuovo, G., Tani, F., Ponti, L., Dewey, D., and Schuldberg, D.

Subjects
Adult, Male, Psychometrics, Substance-Related Disorders, Settore M-PSI/08 - PSICOLOGIA CLINICA, Neuropsychological Tests, Assessment, Developmental psychology, Young Adult, Cognition, Orientation, Diagnosis, medicine, Humans, Biological Psychiatry, Reliability (statistics), Psychiatric Status Rating Scales, Analysis of Variance, Depressive Disorder, Discriminant validity, Middle Aged, medicine.disease, Personality disorders, Psychotherapy, Psychiatry and Mental health, Psychotic Disorders, Schizophrenia, Scale (social sciences), Female, Self Report, Insight, Construct (philosophy), Psychology, Clinical psychology
Abstract

Introduction Given the centrality of insight in promoting change, the relevance of measures for assessing this construct has become increasingly clear. This paper describes a new self-report measure for assessing some of the characteristics of insight, the insight orientation scale (IOS). Aims In study 1, we evaluated the factor structure and the reliability of the scale. In study 2, we analyzed the concurrent and discriminant validity of the scale in patients with different clinical diagnoses. Methods In study 1 participants were 600 individuals (41.1% male, 58.9% female) with a mean age of 33.95 years (SD = 13.04). In study 2 participants were 136 individuals divided into the following groups: 1) schizophrenia spectrum and other psychotic disorders ( n = 26); 2) substance-related disorders ( n = 55); 3) depressive disorders ( n = 27); and 4) personality disorders ( n = 28). Instruments Instruments are the insight orientation scale (IOS) and the Beck cognitive insight scale. Results The goodness-of-fit indices showed a satisfactory fit of a one factor model. We found also a good internal consistency (α = .77). Conclusions These findings support the dimensionality of the IOS and suggest that it may be useful as an assessment tool for use in guiding psychotherapy.

Published
2015

37. Searching for the truth about schizophrenia requires the application of similarly high standards of proof to biological and social risk factors

Author

Alice Mulè, Robin M. Murray, Daniele La Barbera, Lucia Sideli, Murray, RM, Sideli, L, Mulè, A, and La Barbera, D

Subjects
Social risk, Child abuse, medicine.medical_specialty, causality, Schizophrenia (object-oriented programming), childhood abuse, Causality, schizophrenia, Psychiatry and Mental health, Settore M-PSI/08 - Psicologia Clinica, medicine, Psychiatry, Psychology, Childhood abuse, Settore MED/25 - Psichiatria
Abstract

In their provocative paper, Bentall and Varese (2012) criticize our review on child abuse and schizophrenia (Sideli, Mule, La Barbera, & Murray, 2012) and suggest that we have a biological bias whi...

Published
2014

38. Cannabis users have higher premorbid IQ than other patients with first onset psychosis

Author

Jennifer O'Connor, Manuela Russo, Robin M. Murray, Caterina La Cascia, Hannah M Sallis, Marta Di Forti, Valeria Mondelli, Poonam Gardner-Sood, Maria Aurora Falcone, Heather Taylor, Anthony S. David, Paola Dazzan, Simona A. Stilo, Laura Ferraro, Benjamin D.R. Wiffen, Lucia Sideli, Abraham Reichenberg, Bess Friedman, Daniele La Barbera, Antonella Trotta, Ferraro, L., Russo, M., O'Connor, J., Wiffen, B., Falcone, M., Sideli, L., Gardner Sood, P., Stilo, S., Trotta, A., Dazzan, P., Mondelli, V., Taylor, H., Friedman, B., Sallis, H., LA CASCIA, C., LA BARBERA, D., David, A., Reichenberg, A., Murray, R., and Di Forti, M.

Subjects
Adult, Male, medicine.medical_specialty, Psychosis, Marijuana Abuse, First Episode of Psychosis (FEP), Premorbid IQ, Intelligence, Neuropsychological Tests, Substance use, behavioral disciplines and activities, Young Adult, Cognition, Settore M-PSI/08 - Psicologia Clinica, mental disorders, medicine, Humans, Effects of sleep deprivation on cognitive performance, Cannabi, Young adult, Cannabis, IQ, Risk of psychosis, Schizophrenia, Risk of psychosi, Psychiatry, Biological Psychiatry, First episode, Intelligence Tests, Psychiatric Status Rating Scales, Analysis of Variance, Chi-Square Distribution, Intelligence quotient, biology, medicine.disease, biology.organism_classification, Psychiatry and Mental health, Psychotic Disorders, Female, Psychology, human activities, Chi-squared distribution, Clinical psychology
Abstract

Background: A number of studies have reported that patients with psychosis who use cannabis have better cognitive performance than those who do not. This is surprising as cannabis can impair cognition in healthy subjects. An obvious question is whether the better current performance of psychotic patients who have used cannabis is a reflection of their having a higher premorbid IQ than those psychotic patients who haven't used cannabis. Aim: In a sample of patients at their first episode of psychosis, we tested the hypothesis that patients who smoked cannabis would have a higher premorbid IQ than patients who did not. Methodology: 279 participants (119 patients and 160 healthy controls) were assessed in order to obtain current and premorbid IQ measures and detailed information on cannabis use. We examined the association between cannabis use and both premorbid and current IQ in patients and controls. Results: Patients who had ever smoked cannabis had significantly higher current (p < .001) and premorbid IQ (p = .004) compared to patients who had never used cannabis. This difference was not found among controls. Conclusions: These findings suggest that the better cognitive performance of patients with their first episode of psychosis who have used cannabis compared with those who haven't is due to the better premorbid IQ of the former.

Published
2013

39. Do child abuse and maltreatment increase risk of schizophrenia?

Author

Robin M. Murray, Lucia Sideli, Daniele La Barbera, Alice Mulè, Sideli, L, Mulè, A, La Barbera, D, and Murray, RM

Subjects
Child abuse, medicine.medical_specialty, Psychosis, Etiology, child abuse, Poison control, Review Article, Review, Settore M-PSI/08 - Psicologia Clinica, Injury prevention, medicine, Psychiatry, Psychological abuse, Settore MED/25 - Psichiatria, Biological Psychiatry, business.industry, schizophrenia, maltreatment, medicine.disease, Psychiatry and Mental health, Sexual abuse, Schizophrenia, National Comorbidity Survey, business, Clinical psychology
Abstract

INTRODUCTION: IntroductionaaAlthough childhood abuse is a recognised risk factor for depression, post-traumatic stress disorder, and substance misuse, its role in the aetiology of psychotic disorder remained controversial. This is in part because the putative effect of childhood trauma on psychosis has been mostly evaluated by small, cross sectional, uncontrolled studies that raised methodological issues. METHODS: Papers concerning the association between childhood trauma and psychotic disorders (to November, 2011) were identified using a comprehensive search of PubMed, Psychinfo, and Scopus and analysing reference list of relevant papers. A narrative synthesis was used to summarise results. RESULTS: An association between childhood abuse and psychotic symptoms was consistently reported by large cross sectional surveys with an effect ranging from 1.7 to 15. However, we cannot conclude that the relationship is causal as lack of longitudinal studies prevent us from fully excluding alternative explanations such as reverse causality. Gender, cannabis use, and depressive and post-traumatic stress disorder symptoms appear to moderate the effect of childhood trauma on psychotic disorders. However, specificity of childhood abuse in psychotic disorders and, particularly, in schizophrenia has not been demonstrated. CONCLUSION: Although the association between childhood abuse and psychosis has been replicated, the etiological role of such early adversity has yet to be fully clarified. So far none of the studies reported support the hypothesis that childhood abuse is either sufficient or necessary to develop a psychotic disorder. It seems likely that any effect of childhood abuse on schizophrenia needs to be understood in terms of genetic susceptibility and interaction with other environmental risk factors. Language: en

Published
2012

40. EPA-1417 – Migration history and first episode psychosis: Results from EUGEI project- Italy

Author

Thomas Marcacci, Sarah Tosato, Ilaria Tarricone, J. Boydell, Mauro Braca, D. La Barbera, Craig Morgan, Mirella Ruggeri, A. Muè, Domenico Berardi, Tarricone, I., Tosato, S., Muè, A., Ruggeri, M., La Barbera, D., Marcacci, T., Braca, M., Boydell, J., Morgan, C., and Berardi, D.

Subjects
Psychosis, European community, country, business.industry, media_common.quotation_subject, Ethnic group, Distribution (economics), medicine.disease, schizophrenia, Psychiatry and Mental health, Geography, Schizophrenia, First episode psychosis, Unemployment, medicine, Demographic economics, Generalizability theory, business, media_common
Abstract

The excess of psychosis among migrants and ethnic minorities is a well defined phenomenon in North Europe, while it should be still demonstrated in south Europe. Because of the variation in prevalence and distribution of risk factors in different national contexts, similar studies in different countries are needed to test the hypotheses and to ensure the generalizability of the findings. Moreover, available studies have been mostly focused on risk factors of psychosis during the post migration phase (such as ethnic fragmentation, unemployment, etc) and among well established ethnic minorities (second and further generations of migrants). In Italy, first generation migrants are still the larger component of the ethnic minorities’ populations and we can evaluate risk factors of psychosis related to the migration history as whole considered (pre-migration, migration and post migration phases). I will present results on risk factors of psychosis among first generations migrants in the three sites involved in the EU-GEI Project in Italy (Bologna, Palermo and Verona) (European Network of National Schizophrenia Networks Studying Gene Environment Interactions Project EU-GEI European Community's Seventh Framework Program, grant agreement No. HEALTH-F2-2009-241909). Particularly, I will discuss our efforts to understand the role of the migration process characteristics in the development of psychosis.

Published
2014

41. Perceived stigma in patients affected by psychosis: Is there an impact on relapse?

Author

Sideli, L., Seminerio, F., Barone, M.V., Mulè, A., La Cascia, C., Sartorio, C., D’Agostino, R., Ferraro, L., Tripoli, G., Francomano, A., Inguglia, M., Vassallo, G., Majorana, C., and La Barbera, D.

Subjects
*PSYCHOSES, *DISEASE relapse, *SOCIAL stigma, *SCHIZOPHRENIA
Abstract

Introduction The World Health Organization (WHO) considers stigma of mental illness as a crucial problem (WHO, 2001). Stigma contributes to the onset (Morgan et al., 2010) and the outcome of people affected by schizophrenia (Himan, 2015). Objectives To evaluate the perception of patients affected by psychotic disorders of being stigmatized by the community. Aims To compare the perception of stigma among subgroups of patients at different stage of their disorder. Methods Thirty-five patients affected by a first-episode of psychosis (FEP) and 96 patients affected by chronic psychosis were recruited. The Devaluation of Consumers Scale (DCS) and the Devaluation of Consumer Families Scale (DCFS) were administered to assess the perceived public stigma (Struening et al., 2001). The Positive And Negative Schizophrenic Symptoms Scale (PANSS) (Kay et al., 1987) and the Global Assessment of Functioning (GAF) (Goldman et al., 1992) were administered to assess psychotic symptoms and global level of functioning. Results Patients affected by chronic psychosis perceived higher devaluation against mental disorders than patients with a recent onset of psychosis (Mann–Whitney's U = 910.500, P = 0.017). DCS and DCFS correlated with increased voluntary admissions (Rho = 0.355, P = 0.002; Rho = 0.257, P = 0.029) and DCS with increased compulsory admissions (Rho = 0.349, P = 0.003). Only among chronic patients, DCS factor 2 was related to global level of functioning (Rho = 0.217, P = 0.041). Conclusions Patients affected by chronic psychotic disorders perceived a more pessimistic attitude of the community towards their participation in social and community life and this is related to increased admissions and disability. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results